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Abstract 
A Pilot Randomized Controlled Trial Comparing the Efficacy of Problem-Solving Therapy to 
Enhanced Treatment as Usual for Reducing High Blood Pressure 
Lauren Miriam Greenberg 
 
 High blood pressure is a highly prevalent and modifiable risk factor for cardiovascular 
disease that has substantially contributed to disability, morbidity, mortality, health disparities and 
economic burden in the United States. Although relatively easy to diagnosis and inexpensive to 
treat, controlling high blood pressure, thereby reducing its sequelae, remains difficult, 
particularly for Black individuals, due to a host of psychosocial, biological, and environmental 
factors. There is a need to identify an efficacious stress-reduction intervention for lowering 
uncontrolled high blood pressure that can be effectively translated into practice.  
 In the current pilot study, the preliminary efficacy and feasibility of Problem-Solving 
Therapy (PST), compared to telephone-delivered enhanced treatment as usual (ETAU), were 
evaluated on measures of blood pressure, social problem solving ability, medication adherence, 
perceived stress, depression, and health-related quality of life (HRQOL) at baseline, 
posttreatment, and 3-month follow up. Recruitment from outpatient medical clinics yielded a 
sample of 14 participants, predominantly Black and female, with uncontrolled high blood 
pressure, who were randomly assigned to PST or ETAU. Mean differences between conditions 
from baseline to posttreatment assessments were examined using a series of intent-to-treat         
(N = 12) t-tests and repeated measures ANOVAs, none of which were statistically significant. 
Inspection of effect sizes and clinical significance indicated a trend toward efficacy of PST to 
improve medication adherence [F (1, 10) = 2.54, p = 0.14, ηp2 = 0.20] and physical HRQOL     
 xi	  
[F (1,10) = 2.54, p = 0.14, ηp2 = 0.20], as well as slightly more frequent clinically meaningful 
changes in systolic blood pressure, mental HRQOL, and depression for those who received PST. 
In terms of feasibility, about 13% of 108 recruited patients were enrolled, the rate of attrition was 
below 20% for treatment initiators, retention of treatment initiators was 100% for PST (nPST = 6) 
and 83.3% (nETAU = 5) for ETAU at posttreatment, and about 80% of participants rated the 
treatments as credible and effective. Three-month follow up assessments were too few to conduct 
meaningful analyses. Although a trend toward efficacy of PST was indicated, challenges in 
recruitment limited sample size, and, therefore, the aforementioned preliminary results must be 
interpreted with caution. 
 Keywords: high blood pressure, hypertension, Problem-Solving Therapy 
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CHAPTER 1: INTRODUCTION 
1.1. High blood pressure: High blood pressure (BP) is the leading cause of preventable death in 
the United States, a major risk factor for cardiovascular disease (CVD), a substantial contributor 
to morbidity and disability, an important factor in health disparities, and an economic burden on 
the health care system in the U.S. (Chobanian et al., 2003; IOM, 2010; Lloyd-Jones et al., 2010; 
Nwankwo, Yoon, Burt, & Gu, 2013; Roger et al., 2012). Despite the recognition that high BP 
has a significant impact on the health of the nation, as denoted by the Healthy People 2020 
objective HSD-12 (i.e., increasing the proportion of adults whose high BP is controlled), the 
comprehensive report by the Institute of Medicine’s (IOM) Committee On Public Health 
Priorities to Reduce and Control Hypertension in the U.S. Population (2010) described the 
problem as largely neglected. Although high BP relatively easy to diagnose and low-cost to treat, 
“millions of Americans continue to develop, live with, and die from hypertension because we are 
failing to translate our public health and clinical knowledge into effective prevention, treatment, 
and control programs” (IOM, 2010, p. 2).  
The effective translation of evidence-based intervention into practice is challenging, and 
requires a multi-pronged approach because barriers exist at multiple levels, including 
environmental, health care system, and individual (Ogedegbe, 2008; Scisney-Matlock et al., 
2009). Both population-wide interventions (e.g., reduction of salt intake through legislation, salt 
reduction agreements with industry, health education through mass media) and individual 
interventions (e.g., individual education and treatment for high BP) are useful in reducing health 
care burden, with findings suggesting that population-based interventions are more cost-effective, 
but less clinically effective than individual-based strategies (e.g., IOM, 2010). Furthermore, 
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population-based strategies may disproportionately benefit highly educated, affluent subgroups, 
leading to greater health disparities (IOM, 2010). 
1.1.1. Definition: Blood pressure (BP) refers to the force of blood against the walls of the 
arteries; when elevated over time, it is referred to as high blood pressure (Chobanian et al., 2003). 
High BP causes the heart to work harder and contributes to atherosclerosis, the term for the 
hardening of the arteries (Chobanian et al., 2003). Hypertension, the medical term for high BP, is 
defined as a systolic BP (SBP) greater than or equal to 140 millimeters of mercury (mmHg), and/ 
or a diastolic BP (DBP) greater than or equal to 90 mmHg (e.g., Chobanian et al., 2003; Lloyd-
Jones et al., 2010; Roger et al., 2012; Yoon et al., 2010). Hypertension is also indicated when an 
individual is prescribed antihypertensive medication to lower BP or has been told by a physician 
or other health professional on at least two occasion that BP is high (e.g., Chobanian et al., 2003; 
Lloyd-Jones et al., 2010; Roger et al., 2012; Yoon et al., 2010). Hypertension is categorized as 
either primary (essential) hypertension or secondary hypertension; primary hypertension is the 
name given to high BP without a known cause, representing 90-95% of all cases of hypertension, 
whereas secondary hypertension is the result of an already existing medical condition, such as 
Cushing’s syndrome or thyroid problems (Carretero & Oparil, 2000). High BP is further 
classified into Stage 1 hypertension (140-159 mmHg SBP or 90-99 mmHg DBP) or Stage 2 
hypertension (greater than or equal to 160 mmHg SBP or greater than or equal to 100 mmHg 
DBP); for those with diabetes or chronic kidney disease (CKD), high BP is defined as 130/80 or 
higher (e.g., Chobanian et al., 2003).  
1.1.2. Prevalence: According to data from the National Health and Nutrition Examination Survey 
(NHANES) 2011-2012, high BP affects approximately 29.1% adults in the U.S. (Nwankwo et al., 
2013). Projections for the year 2030 show rising prevalence estimates of hypertension, with an 
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expected increase of 9.9%, an additional 27 million Americans (Heidenreich et al., 2011). The 
prevalence of hypertension is nearly equal between men and women, though age-adjusted 
estimates vary  (Roger et al., 2012).  
1.1.3. High blood pressure control: In 2012, when the eligibility criteria for this study were 
established, BP control guidelines from the Seventh Report of the Joint National Committee on 
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) were used to 
operationally define what constituted BP goals, which at the time was achieved with a BP of 
<140/90 mmHg, or <130/80 mmHg for patients with diabetes or CKD (Chobanian et al., 2003). 
Since that time, targeted goals for BP in patients 60 years or older have continued to be debated; 
the American College of Cardiology (ACC) and the American Heart Association (AHA) 
recommend a goal of BP below 140/90 mmHg, whereas the most recent guidelines from the 
Eight Report of the JNC (JNC 8) suggest a goal of 150/90 mmHg or below. Of the approximately 
30% of adults in the U.S. with hypertension, about 20% are unaware of having the condition, 
partly due to the lack of symptoms; control has been achieved in about 44% of those aware of 
their high BP (Chobanian et al., 2003; Egan et al., 2010; Roger et al., 2012). 
1.1.4. Minority health disparities: Prevalence rates of high BP are the highest in the world for 
African Americans and it is on the rise in this population (Roger et al., 2012). The average BP 
for African Americans is higher than that of any other ethnicity and they tend to develop high BP 
earlier in life; additionally, African Americans are less likely to reach BP control, with rates of 
control 27% lower in Blacks than Whites (Roger et al., 2012). Biological differences (e.g., 
genetic traits, higher retention of salt) and environmental and behavioral characteristics (e.g., 
medication adherence, dietary habits, stress) have been delineated in proposed explanations of 
higher prevalence in a Black population (Fuchs, 2011). Particularly relevant to this study, 
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researchers have identified various factors that influence medication adherence in this population, 
including the mistrust of health care providers, perceived discrimination in health care partly 
based upon historical events (e.g., the Tuskegee Study), low health education, and beliefs that 
medication is harmful and/or ineffective (Flack et al., 2010, Fongwa et al., 2008; Forsyth, 
Schoenthaler, Chaplin, & Ogedegbe, 2014; Lukoschek, 2003; Yancey, Ortega, & Kumanyika, 
2006).  
1.1.5. Morbidity: Hypertension is a major risk factor for heart disease and stroke, the first and 
third leading causes of death in the U.S., respectively (e.g., Roger et al., 2012). Evidence 
suggests the relationship between BP and CVD events is continuous, consistent, and independent 
of other risk factors (e.g., smoking, high-density lipoprotein or left ventricular hypertrophy), 
down to at least 115/75 mmHg; the higher the BP, the greater the risk of other conditions, 
including heart failure, myocardial infarction, stroke and kidney disease (e.g., Chobanian et al., 
2003; Lewington, Clarke, Qizilbash, Peto, & Collins, 2002; Roger et al., 2012). According to Gu 
and colleagues (2008), SBP, compared to DBP, is considered a more important risk factor for 
CVD. 
1.1.6. Mortality: High BP has been called the “silent killer,” referring to the typical absence of 
symptoms until vital organs (e.g., heart, brain, kidneys) are damaged (Lukoschek, 2003). The 
age-adjusted hypertension-related mortality rate (i.e., any mention of hypertension on the death 
certificate) has risen 23.1% from 2000 to 2013 (i.e., from 255.1 per 100,000 in 2000 to 314.1 in 
2013), whilst the rate for all other causes of death combined decreased 21.0%; rates were highest 
among the non-Hispanic Black population compared with the non-Hispanic White and Hispanic 
populations (Kung & Xu, 2015). Kung and Xu (2015) reported the top five underlying causes of 
hypertension-related deaths were heart disease, hypertension, stroke, cancer and diabetes. 
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1.1.7. Cost: The direct and indirect cost of high BP in 2008 was about 50.6 billion (Roger et al., 
2012). According to Roger and colleagues (2012), the number of medical visit for hypertension 
in 2009 was estimated to be slightly greater than 55 million (i.e., slightly less than 50 million 
physician office visits, about 1 million emergency department visits, and slightly more than 4 
million outpatient department visits) and hypertension was listed as either a primary or 
secondary diagnosis slightly more than 9 million times for hospitalized inpatients. 
1.1.8. Summary: High BP is a chronic condition that is present at an alarmingly high rate, with 
considerable impact on public health. Research has shown a strong, continuous, graded, 
consistent, independent and predictive relationship between high BP and vascular disease (IOM, 
2010). High BP has significant health sequelae at present and prevalence is projected to increase, 
indicating a significant need to prioritize the effective implementation of efficacious prevention, 
treatment, and control programs (IOM, 2010).  
1.2. Psychosocial stress: Stress is ubiquitous and those in the U.S. experience higher levels of 
stress than they believe to be healthy (American Psychological Association, 2012). Evidence 
suggests that psychosocial stress plays an important role in contributing to the development and 
prognosis of CVD in general and, specifically, in hypertension, such that some proponents have 
called for the standard evaluation and treatment of psychosocial stress and depression for 
patients with these conditions (e.g., Bosworth & Oddone, 2002; Chobanian, et al., 2003; Krantz, 
Sheps, Carney, & Natelson, 2000; Linden, 2003; Lloyd-Jones et al., 2010; Nezu, et al., 2011; 
Sparrenberger et al., 2009; Spruill, 2010). Recognizing the impact of psychosocial factors on 
blood pressure, various treatments (e.g., behavioral therapies, meditation including 
Transcendental Meditation, yoga, relaxation therapies, biofeedback approaches) have been 
developed to reduce arousal in response to stress and/ or the presence of stress, but the evidence-
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base of such treatments has been considered inadequate or inconsistent (Bosworth et al., 2011; 
Blumenthal, et al., 2002; IOM, 2010; Linden, Stossel, & Maurice, 1996; Rainforth et al., 2007).  
1.2.1. Psychosocial factors: A host of psychosocial factors (e.g., chronic stressors, perceived 
stress, emotional factors, motivation, avoidant coping, self-efficacy, functional social support, 
health literacy) contribute to uncontrolled high BP (e.g., Bosworth & Oddone, 2002; Magrin et 
al., 2014; Rozanski, Blumenthal, Davidson, Saab, & Kubzansky, 2005; Rod et al., 2009; 
Rutledge & Hogan, 2002; Sparrenberger, et al., 2009). Common chronic stressors include work 
stress, marital stress, caregiver strain, low socioeconomic status, and low social support (e.g., 
Rozanski et al., 2005). Although acute life events have been associated with hypertension, 
chronic stress has been identified as more likely to contribute to sustained BP elevation 
(Sparrenberger et al., 2009). Stressful events may lead to negative cognitive-affective coping 
responses, which may maintain physiological arousal whether or not the stressor is actually 
present; examples of this are worry and rumination, or anticipating future stress or dealing with 
past stress, respectively (e.g., Krantz et al., 2000). Common emotional factors include depression, 
anxiety, hostility and anger; of these, depression has been most widely studied in recent years, 
with findings suggesting depression increases the risk of adverse cardiac events (e.g., Krantz et 
al., 2000; Larzelere & Jones, 2008; Rozanski et al., 2005). Worry has also established affecting 
high BP and high BP control, particularly in African Americans (Bosworth, et al., 2008). 
Disconcertingly, compared to lifestyle behaviors (e.g., diet and physical activity), health care 
providers are less likely to assess and treat psychosocial risk factors possibly due to limited 
familiarity with effective strategies and recommendations (e.g., Rozanski et al., 2005).  
1.2.2. Pathophysiology: Psychosocial stress is associated with the activation of the hypothalamic-
pituitary-adrenal (HPA) axis and sympathetic nervous systems (SNS); catecholamines and 
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corticosteroids are released, which lead to increased heart rate, cardiac output, and BP (e.g., 
Krantz & Manuck, 1984; Lambert & Lambert, 2011; Spruill, 2010). The HPA and SNS response 
to acute stress appears well documented but the process through which stress contributes to 
prolonged elevation of BP over time is not as well understood; repeated activation, failure to 
return to resting levels after a stressful event, dysregulation of control and/or an excessive level 
of circulating cortisol and catecholamines, down-regulation in cortisol receptors leading to 
deficits in proinflammatory cytokine regulation, failure to habituate to a repeated stressor, or 
some amalgamation of these mechanisms may impair physiological and metabolic functions and 
be responsible for the development of hypertension (e.g., Lambert & Lambert, 2011; Larzelere & 
Jones, 2008; McEwen, 1998; Spruill, 2010).  
1.2.3. Behavioral impact: Stress, including situational and cognitive-affective forms, indirectly 
impacts high BP through unhealthy lifestyle behaviors. Stress promotes poor diet, smoking, 
physical inactivity, and nonadherence to medical regimens (e.g., Claar & Blumenthal, 2003; 
Larzelere & Jones, 2008). In turn, these behaviors alter physiological processes thereby resulting 
in further development and progression of high BP and heart disease (Claar & Blumenthal, 2003). 
Rod and colleagues (2009) demonstrated the effect of stress on health behaviors, finding that 
individuals with high levels of perceived stress were less likely to quit smoking, more likely to 
become physically inactive, less likely to refrain from drinking alcohol above sensible limits, and 
more likely to be overweight compared to those with low levels of stress. Nonadherence to 
antihypertensive medication and lifestyle recommendations commonly interferes with high BP 
control; depression has been identified as impacting the likelihood of nonadherence with 
treatment recommendations, threefold and self-efficacy has been positive associated with 
medication adherence among African Americans (DiMatteo, Lepper, & Croghan, 2000; Warren-
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Findlow, Seymour, Brunner Huber, 2011). Although psychosocial factors also influence lifestyle 
behaviors (e.g., medication adherence), thereby contributing to poorer high BP control, health 
care providers are more likely to assess lifestyle behaviors themselves, rather than psychosocial 
factor that may serve as barriers (e.g., Rod, Gronbaek, Schnohr, Prescott, & Kristensen, 2009; 
Rozanski et al., 2005; Warren-Findlow, Seymour & Brunner Huber, 2011). 
1.2.4. Stress management: Stress reduction strategies consist of techniques that reduce excessive 
arousal to stress by changing cognitive, emotional, and/or physiological reactions to stress; this 
may occur by enhancing the ability to minimize the negative impact of stress on physical or 
emotional responses, cope effectively with situations leading to a negative stress response, and 
minimize the occurrence of stressors (e.g., Nezu, et al., 2011). Thus far, the evidence for stress-
reduction interventions to reduce high BP has largely been considered inadequate (e.g., Brook et 
al., 2013; IOM, 2010); however, the National Institute for Health and Clinical Excellence (2011) 
recognized relaxation therapies, including stress management, meditation, and cognitive 
therapies, can serve as adjunctive lifestyle interventions that can reduce high BP, citing modest 
and varied reductions. Although research is limited and treatment components may vary, meta-
analyses suggest that stress reduction approaches, particularly meditation and individualized 
multi-component cognitive behavioral stress management therapies (CBSM), may significantly 
reduce high BP (Blumenthal, Sherwood, Gullette, Georgiades, & Tweedy, 2002; Rainforth et al., 
2007).  
1.2.5. Summary: Extensive research has revealed the effects of psychosocial stress on high BP 
and further CVD; direct and indirect effects of psychosocial stress indicate the potential benefit 
of targeting psychosocial stress through intervention. Thus far, psychosocial interventions aimed 
at reducing high BP, including stress management/ reduction and behavioral interventions, have 
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yielded inconsistent and modestly efficacious findings, emphasizing the need for identifying an 
effective, multicomponent, standardized cognitive and behavioral stress management 
intervention to supplement established treatments (e.g., antihypertensive medication). 
1.3. Problem-Solving Therapy:  
1.3.1. Social Problem-Solving Theory: Social problem solving (SPS), on which Problem-Solving 
Therapy (PST) based, represents the multidimensional meta-process of ideographically 
determining and selecting coping responses to address the unique features of a given stressful 
situation at a given time (e.g., Nezu, 2004; Nezu & Nezu, 2012; Nezu, Nezu, & D’Zurilla, 2013). 
Contemporary SPS theory consists of two main dimensions, problem orientation and problem-
solving style. Problem orientation, comprised of two orthogonal (positive and negative) types, 
refers to the relatively stable cognitive-affective schemas that characterize an individual’s beliefs, 
attitudes, and emotional reactions regarding problems in living and one’s ability to cope with 
such problems (Nezu & Nezu, 2012). Problem-solving style (i.e., rational problem solving, 
avoidant problem solving, and impulsive-careless problem solving) represents the core 
cognitive-behavioral activities that individuals engage in when attempting to solve stressful 
problems (Nezu & Nezu, 2012).  
1.3.2. Therapeutic intervention: The premise of PST is based on a model demonstrating the 
relationship between SPS and distress (Nezu & Nezu, 2012; Nezu, et al., 2013). The overall goal 
of this psychosocial intervention is to foster the adoption and effective implementation of 
adaptive problem-solving attitudes (i.e., optimism, enhanced self-efficacy) and behaviors (i.e., 
adaptive emotional regulation, planful problem solving) to improve physical and mental health 
(Nezu, et al., 2013). Effective coping involves learning skills geared toward successfully 
resolving stressful problems and/or learning to better manage negative emotional reactions to 
 10	  
stressors (Nezu & Nezu, 2012; Nezu, et al., 2011). According to Nezu and colleagues (2011), a 
key therapeutic target of PST is altering attitudes or beliefs that impede attempts to cope 
adaptively with stressful problems. This major objective is supplemented with other treatment 
components to help individuals better manage negative emotions and engage in effective rational 
problem-solving activities (e.g., setting realistic goals, identifying barriers to reaching such goals, 
creatively thinking of various alternative solutions, deciding which alternatives may lead to 
success, and monitoring and evaluating the solution action plan). For a review of SPS theory and 
PST application, see Nezu and Nezu (2012) and Nezu and colleagues (2011). 
1.3.3. Evidence base: PST is an evidenced-based cognitive behavioral intervention used to 
promote the effective application of adaptive problem-solving attitudes and skills to solve 
stressful problems in everyday living (e.g., D’Zurilla & Goldfried, 1971; Nezu, 2004; Nezu & 
Nezu, 2012; Nezu et al., 2013; Nezu, Nezu, Houts, Friedman, & Faddis, 1999). Across multiple 
populations, when under similar levels of stress, individuals with poor SPS have been 
consistently found to experience significantly high levels of psychological distress as compared 
to individuals with effective SPS (Nezu & Nezu, 2012). PST has been found efficacious in 
reducing multiple types of distress and evidence suggests that ineffective SPS is associated with 
a variety of poor health outcomes (e.g., Hill-Briggs, et al., 2006; Malouff, Thorsteinsson, & 
Schutte, 2007). Malouff and colleagues (2007) conducted a meta-analysis of 32 studies, 
capturing nearly 3,000 participants, that evaluated the efficacy of PST across various mental and 
physical health problems; the researchers concluded that PST was equally as effective as other 
psychosocial treatment and significantly more effective that both no treatment and attention 
placebo conditions. Specifically within a population with hypertension, one study employed a 
multi-component stress management protocol, consisting of PST, education and relaxation 
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training and found that those who received the intervention showed significant reductions in BP 
compared to a wait list control condition at posttreatment and 4-month follow-up (García, 
Labrador, & Sanz, 1997). Additional correlational and mediational analyses indicated that 
improvements in SPS were responsible for the effects of the stress management protocol, 
suggesting that PST was at least an active treatment ingredient (García-Vera, Sanz, & Labrador, 
1998; Nezu & Nezu, 2012).  
1.3.4. Efficacy and acceptability in ethnic minority populations: Although low-income minority 
populations are underrepresented in randomized clinical trials of cognitive-behavior therapies 
(CBTs), there is indication that CBT may be preferred by ethnic minorities in that it is a concrete, 
didactic, directive and active type of intervention from an expert that targets current problems 
(Nezu, Greenberg, & Nezu). PST has been evaluated as a treatment for depression among Black 
and Hispanic persons, although available evidence is limited, findings thus far suggest PST is 
both acceptable and effective in these populations (Ell et al., 2009; Kasckow et al., 2010).  
1.3.5. Treatment tailoring: As discussed by Nezu and Nezu (2012), contemporary PST is 
designed in such a way that it facilitates the tailoring of treatment to a given population; in this 
case, PST was modified with two major considerations: a) fit with high BP and b) relevance to a 
low-income African American population. Because prevalence rates of uncontrolled high BP are 
higher in Black people, and sampling was performed in the City of Philadelphia, of which the 
racial distribution of residents is 43.4% Black, the sample was expected to consist of mostly 
Black individuals (United States Census Bureau, 2010). The standardized treatment manual (see 
Appendix B) was adapted to include examples and common problems a low-income Black 
patient with high BP might experience (e.g., coping with disability, anger, financial problems, 
family problems). In addition to the evaluation of social problem-solving attitudes and beliefs, 
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the therapeutic process itself involves collaboration with patients to identify current real-life 
problems and goals as well as the generation, implementation, and evaluation of specific, 
concrete strategies for coping with stated problems to the identified goal. As with PST, and many 
other cognitive-behavioral treatments, one aim of PST was to teach patients the skills for coping 
with current and future problems, rather than attempts at solving problems for participants. 
1.3.6. Summary: Grounded in stress-diathesis model, PST has been found efficacious in reducing 
stress and distress among various populations, including medical patients (e.g., Nezu & Nezu, 
2012; Nezu, Nezu, & Xanthopoulos, 2011). Given the aforementioned links between high BP 
and psychosocial factors, including chronic stressors, cognitive-affective variables, and 
behavioral responses, it was surmised that PST would be particularly suitable for reducing 
uncontrolled high BP. Evidentiary support for multicomponent cognitive-behavioral stress 
management interventions, the impact of psychosocial stress on high BP and lifestyle behaviors, 
and barriers to medication adherence, a common problem in uncontrolled high BP, all align with 
the theory, clinical targets, and skills that comprise PST. Figure 1 illustrates the conceptualized 
role of SPS ability in the relationship between stress and health, showing that improved SPS 
ability may prevent or mitigate negative health consequences of stress.  
1.4. Current study aims: In consideration of the importance of developing and testing 
interventions that translate to evidence-based practice, and the health disparities present in 
minority populations, this trial was designed to balance internal and external validity. It was 
conducted in a real-world setting with community restraints, while maintaining control over 
threats to validity through standardization and randomization. The overarching goals of this pilot 
study were: a) examining preliminary efficacy of PST for reducing high BP and improving 
various psychosocial outcomes, as compared to an educationally based enhanced treatment-as-
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usual (ETAU) condition and b) evaluating the feasibility of a PST intervention in the context of 
an urban medical setting. 
1.4.1. Preliminary efficacy hypotheses: A major objective of this study was to determine the 
preliminary efficacy of PST, compared to that of a telephone-delivered educationally based 
ETAU condition, in patients with high BP. A series of hypotheses extend from the limited 
efficacy testing, as discussed below; briefly, these include evaluating changes in SBP and DBP, 
SPS ability, medication adherence, mental and physical health-related quality of life (HRQOL), 
perceived stress and depressive symptoms between participants receiving either PST or ETAU 
from baseline to posttreatment. 
Hypothesis 1(a&b): It was hypothesized that participants in the PST condition would, on 
average, show statistically significantly greater reductions in BP [a) systolic and b) diastolic], 
compared to those in the ETAU condition, from baseline to posttreatment (H1: µPST > µETAU). 
 Hypothesis 2: On average, those in the PST condition will show statistically significantly 
greater improvements in SPS ability as compared to those in the ETAU condition from baseline 
to posttreatment (H2: µPST > µETAU). 
 Hypothesis 3: On average, those in the PST condition will show statistically significantly 
greater improvements in medication adherence as compared to those in the ETAU condition 
from baseline to posttreatment (H3: µPST > µETAU). 
 Hypothesis 4: On average, those in the PST condition will show statistically significantly 
greater improvements in mental and physical HRQOL as compared to those in the ETAU 
condition from baseline to posttreatment (H4: µPST > µETAU). 
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 Hypothesis 5: On average, those in the PST condition will show statistically significantly 
greater reductions in perceived stress as compared to those in the ETAU condition from baseline 
to posttreatment (H5: µPST > µETAU). 
Hypothesis 6: On average, those in the PST condition will show statistically significantly 
greater reductions in depression as compared to those in the ETAU condition from baseline to 
posttreatment (H6: µPST > µETAU). 
1.4.2. Treatment feasibility: PST is considered a successful intervention for various populations 
in various settings (Nezu & Nezu, 2012); the current study is an expansion of PST for patients 
with high BP in an urban area. In consideration of the possibility of a larger RCT, this 
investigation served as a pilot trial to test the feasibility of implementing a full scale RCT. 
Feasibility was assessed using data gathered through recruitment and enrollment processes, 
intervention implementation, and acceptability of treatment; feasibility included the number of 
patients assessed for eligibility and enrolled, average days to complete eight sessions of 
treatment, and completion rates, as defined by a minimum of 6 session (i.e., after major treatment 
components have been delivered, to bring out the desired effect) and patient feedback on the 
credibility and effectiveness of the treatment.  
Hypothesis 7: It was hypothesized that 80% of participants would be retained in the PST 
treatment, as defined as having attended at least 6 sessions of PST. Additionally, it was expected 
that the overall attrition rate for this trial would be 20% of less (see JARS flow diagram, Figure 
2).  
 Hypothesis 8a: Both the ETAU and PST conditions were standardized and, given the 
frequency of one session per week (i.e., eight weeks), were expected to be delivered over the 
course of eight (56 days) to eleven weeks (77 days) for the full treatment protocol.  
 15	  
 Hypothesis 8b: With regard to time elapsed between eighth session and posttreatment 
assessment and between posttreatment assessment and 3-month follow-up assessment, it was 
hypothesized that the time elapsed would be 0-14 days and 90-105 days, respectively.  
Hypothesis 9: It was hypothesized that a substantial majority, about 80% of participants, 
in the PST condition would find the treatment acceptable (i.e., credible, effective, and 
confidently recommend it), as indicated by a rating of 4 or above on a 5-point Likert scale (1 = 
completely disagree to 5 = completely agree) on items of the program evaluation questionnaire. 
1.4.3. Exploration of maintained effects: In an effort to examine the maintenance of potential 
gains, outcome data was collected 3 months post treatment completion; due to the limited 
number of participants that completed this phase of the study, basic descriptive data is provided. 
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CHAPTER 2: METHODS 
2.1. Participant characteristics 
2.1.1. Eligibility Criteria: To be eligible to participate in this research study, individuals must 
have: (a) presented with persistently high BP (i.e., BP > 140/90 mmHg on two or more 
occasions) or have a current diagnosis of hypertension given or confirmed by a board certified 
(e.g., internal medicine or cardiology) physician; (b) uncontrolled high BP in which the BP goal 
(i.e., BP <140/90 mmHg or <130/80 mmHg for patients with diabetes or chronic kidney disease, 
according to JNC 7 guidelines) had not been met; (c) been between 18 and 75 years of age (d) be 
able to read and understand the consent form; and (e) been able and willing to provide informed 
consent, which includes access to medical records as it pertains to any current or previous 
cardiovascular problems or related diseases. 
2.1.2. Exclusion Criteria: Given the impact on high BP, the following conditions excluded an 
individual from enrollment in this investigation: (a) a current state of decompensated heart 
failure or a diagnosis of heart failure requiring inotropic agents; (b) currently receiving 
chemotherapy or radiation therapy; (c) currently receiving dialysis; (d) a heart attack/myocardial 
infarction during the previous six months; (e) a current or planned pregnancy within six months 
of treatment initiation; (f) hospitalization in the past two months for hypertension-related or 
psychiatric reasons, as this may indicated instability of the condition and/ or affect receipt of 
medication over which the patient may not have control; (g) currently receiving psychotherapy/ 
counseling; (h) taking psychotropic medication that may impact outcomes (e.g., depression) 
without stable dosage and/or with planned change(s) in dosage within six months of treatment 
initiation. 
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2.1.3. Major demographic characteristics: This sample consisted of individuals from the 
Philadelphia metropolitan area who received health care in an urban academic medical setting. 
Table 2 contains the sample means, standard deviations, and percentages of socio-demographic 
variables as well as relevant medical information. The age of total participants ranged from 35-
71 years, with an average age of 58.58 (SD = 10.58) years [METAU = 56.17 (11.62), MPST = 61.00 
(9.86)]. The majority of participants were female (66.7%; nETAU = 4, nPST = 4). The racial 
composition of the sample was predominantly Black non-Hispanic 75% (nETAU = 4, nPST = 5), 
with only 12.5% (nETAU = 2) White non-Hispanic and 6.3% (nPST = 1) Asian non-Hispanic 
participants. This sample was comprised of a preponderance of Black persons and females, even 
higher than the distribution of those two demographics in the City of Philadelphia (United States 
Census Bureau, 2010). In terms of socioeconomic status, the most commonly reported estimated 
yearly household income was less than $20,000 (41.7%; nETAU = 2; nPST = 3) and the average 
years of education was 14.17 (SD = 2.17, range 12-18 years). Regarding job status, 33.3% of 
participants reported working full-time (nETAU = 2, nPST = 2), 25% were retired (nETAU = 1, nPST = 
2), 25% receiving disability/ government subsidy (nETAU = 2, nPST = 1), and 16.7% unemployed/ 
seeking work (nETAU = 1, nPST = 1). In this sample, 41.7% of participants indicated marital status 
as divorced/ separated (nETAU = 3, nPST = 2), 33.3% as single/ never married (nETAU = 1, nPST = 3), 
and 25% as married/ living with partner (nETAU = 2, nPST = 1). All participants indicated they 
considered themselves religious or spiritual. In addition to the aforementioned sociodemographic 
variables, Table 1 also reflects self-reported medical comorbidities (e.g., diabetes, chronic kidney 
disease, cancer, human immunodeficiency virus, stroke, heart failure, obesity, sleep apnea), with 
66.7% reporting at least one medical comorbidity (nETAU = 4, nPST = 4), the most common of 
which was diabetes (41.7%; nETAU = 2, nPST = 3). 
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2.2. Sampling procedures/ Recruitment: At the inception of recruitment, the calculated pool of 
potential participants within the target population was 15 patients per week (an estimated 25% of 
the sixty medical outpatients seen per week in a nephrology clinic had uncontrolled high BP). 
Access to potential participants was influenced by environmental factors (e.g., canceled 
appointments due to weather, transportation problems) and collaboration with physicians and 
staff (e.g., relationships developed with multiple providers, a few of whom vacated their 
positions at the hospital during recruitment). In addition to access, the likelihood of participation 
was considered. Research by Lang and colleagues (2013) and Wendler and colleagues (2006) 
found 73% and 45.3% of African Americans were willing to participate in health-related 
research and clinical intervention studies, respectively. Based on this literature, and in 
consideration of exclusion criteria, it was anticipated that about 25% of those with uncontrolled 
high BP would express interest in and be eligible to participate in the study. Of the estimated 
three to four potentially eligible and interested patients, approximately 50% were expected to 
enroll (i.e., one to two patients per week). As suggested in past research, efforts were made to 
attract Black individuals into this study through monetary compensation, conveyance of respect, 
advertisements showing the potential benefits of participation, flexible scheduling of assessments 
and reminders of assessments via telephone calls; however, due to limited resources, community 
outreach and partnerships were not feasible (Lang et al., 2013; Lukoschek, 2003; Yancey et al., 
2006). An attrition rate for this study was expected to be similar to rates found in treatment 
outcome studies for stress management and PST among medical populations, which generally 
ranged from 12-25% (Davis & Addis, 1999; Nezu, Nezu, Felgoise, McClure, & Houts, 2003; 
Oxman, Hegal, Hull, & Dietrich, 2008). Thus, an initial timeline for recruitment was about 
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twelve months; after about twenty months, only fourteen patients had been enrolled in the study; 
for detail analysis, see discussion on feasibility. 
2.2.1. Sampling method: Participants included individuals referred by health care providers who, 
at the time of referral, met eligibility criteria by having (a) high BP that was (b) uncontrolled. 
Health care providers were given instruction to invite/ refer any individual that meets criteria (a) 
and (b) to participate in the study, unless ineligibility is known, and avoid selection bias; this 
served as an initial pre-screening of patients. For in-person recruitment in one clinic, a research 
assistant approached a pre-screened patient after a ‘warm handoff’ from a physician. When in-
person recruitment was not an option, it was requested that physicians provide the pre-screened 
and potentially interested patient with a study brochure, or, with permission from the patient, 
confidentially relay the contact information of the pre-screened patient to study personnel. Once 
referred and/or contacted, potential participants were given information about the research study 
and, if still interested and seemingly eligible, an appointment was scheduled with a research 
assistant to review the consent form and possibly complete the baseline assessment. If the patient 
was not randomized due to ineligibility or other constraints, local referrals/resources were 
provided. Medical records were used to confirm eligibility.  
2.2.2. Setting: Participants were recruited from outpatient medical clinics within Drexel 
University College of Medicine (DUCOM), a University-affiliated hospital network in 
Philadelphia. Recruitment began in hypertension and nephrology clinics, and was later expanded 
to the women’s health clinic, endocrinology clinic, and finally an internal medicine clinic. The 
option for community referrals were also approved by the institutional IRB, but due to limited 
resources, no advertisement or outreach was conducted to elicit participation from members of 
the community. Individuals from the community were occasionally referred to the study by a 
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family member or friend; these individuals were required to provide the contact information of a 
physician who could confirm the presence of uncontrolled high BP, but none were interested and 
eligible. 
2.2.4. Agreements and Payments: Participants were compensated for assessments as follows: $5 
(baseline), $20 (posttreatment) and $20 (3-month follow up) for a total of $45 (payment per 
participant). 
2.2.5. Institutional Review Board: The study protocol was approved by the Institutional Review 
Board of Drexel University.  
2.3. Sample size, power, and precision: This study did not reach the sample size of 52, 
estimated for sufficient power given planned analyses (Cohen, 1992). Due to inadequate power 
to detect statistical significance at p < 0.05 without a large effect, and standard errors that 
indicated generally wide confidence intervals (CIs) poor precision, the primary focus was on 
effect size estimates. Fourteen participants were enrolled and randomized in this investigation, 
twelve of which initiated treatment (two unable to schedule a first session), and eleven of which 
completed treatment (one dropped out of treatment after two sessions; ten completed the full 
eight sessions of the program). Regarding 3-month follow-up assessment, seven participants 
completed the assessment (nETAU = 4; nPST = 3, unable to reach one participant after 
posttreatment; n = 3 that had not yet completed the assessment). See Figure 2 for a depiction of 
this in a JARS flow diagram. 
During the development of this research study, a priori power analysis indicated that a 
sample of 52 participants would allow researchers to detect mixed model interactions with a 
large effect size, α = 0.05, and power of 0.80 (Cohen, 1992; Faul, Erdfelder, Lang, & Buchner, 
2007). Although the efficacy of PST in this population had yet to be determined, results of a 
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meta-analysis conducted by Malouff and colleagues (2007) indicated that PST was statistically 
significantly more effective than treatment-as-usual and attention placebo across varying types of 
mental and physical health problems, with reportedly medium effect sizes (d = 0.54 compared to 
either condition). Additionally, these researchers also identified three factors associated with 
effect size, participation of PST developers, assigned homework, and training in problem 
orientation, all of which were present in this study (Malouff et al., 2007).  Although the efficacy 
of PST has not been examined in a population with high BP before and therefore it cannot be 
assumed, there is indication that it may produce medium to large effect sizes. 
2.4. Randomization: Random allocation was generated using a random numbers table, stratified 
by sex, with a randomly permuted block size of four and six. Block sizes of four and six were 
chosen to control the distribution of participants in each condition; block sized were small given 
the expectation of less than 30 participants enrolled in the study and randomly varied to increase 
the difficultly of guessing an assignment.  
The sequence of random assignment was concealed from assessors. Randomly assigned 
conditions were sealed in envelopes and revealed only after a consenting participant completed 
his/ her baseline assessment. An individual experienced in generating random numbers tables 
and uninvolved in recruitment, assessment or intervention delivery, created the random numbers 
table prior to commencing any participant allocation. Research assistants were provided with 
standard, manualized training in study-related procedures, which included detailed consent and 
assessment procedures, as well as the steps involved in the allocation of a predetermined random 
assignment. The research assistant/ assessor that delivered the random assigned was documented 
so that person did not complete any future assessment of that given participant, ensuring every 
assessor was masked to the assigned treatment of the participant being assessed. After the 
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random assignment, participants received an explanation of the condition to which they were 
assigned, afforded opportunity to ask questions about the assignment, given treatment materials, 
and provided with information about contact with the participant’s ‘health coach’ (i.e., 
interventionist). 
2.5. Masking: Each participant’s assessor was masked to the randomly assigned condition prior 
to the assessment. Participants were instructed to refrain from discussing any aspect of the study 
with the assessor at posttreatment and 3-month follow up assessments. Intervention deliverers 
and participants were not masked to the condition due to the differing content and delivery 
method of the two conditions; therefore, intervention deliverers were aware of the condition 
assignment, as were participants. All data collected during assessments were de-identified using 
a unique participant number. Intervention deliverers were masked from the participant’s 
assessment data. The individual responsible for random assignment generation did not have 
access to the assessment data. 
 Assessors were masked to the assigned condition of individuals prior to conducting the 
assessment, and the interventionists were masked to individual assessment data through the use 
of password-protected databases. A select few research assistants were aware of the 
identification number associated with the consent and assessment data as necessary.  
2.6. Measures: See Table 1 for a list of measures given at each timepoint and see Appendix D 
for employed measures. 
2.6.1. Blood pressure: Three measures of BP contribute to the adverse effects of hypertension: 
average level, diurnal variation, and short term variability; the average level is considered to be 
the measure most clearly linked to morbid events and some evidence suggests BP variability may 
be a risk factor for cardiovascular morbidity in particular (e.g., Pickering, 2005). In this study, 
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the average level of BP was measured and designated as the primary BP outcome variable. A 
reduction of 5 mmHg was considered clinically meaningful (Whelton et al., 2002).  
 Trained personnel used an automatic BP monitor (Omron 3 series, BP710) to read each 
participant’s SBP, DBP and pulse. According to the Omron Instruction Manual for the 
Automatic Blood Pressure Monitor Model BP710 (HEM-7113-Z), the automatic BP monitors 
used in the study has been calibrated to +3mmHg or 2% of the reading. The Omron automatic 
BP monitor has been tested in accordance with protocols of the Association for the Advancement 
of Medical Instruments (AAMI) and the European Society of Hypertension (Grim & Grim, 
2010). This method of reading BP is commonly used in outpatient medical clinics. A mercury 
sphygmomanometer using the Korotkoff sound technique was not chosen for use in this 
investigation, despite having been the standard approach for clinic BP monitoring for decades 
(Pickering, 2005); due to concerns about reliability when performed by research assistants 
without experience in this method, feasibility, practicality and environmental safety of a mercury 
sphygmomanometer, an automatic BP monitor was preferable for use in this study. 
 Assessor competency was determined by observation and evaluation of the correct 
procedures according to the instruction manual. Trainees were required to watch an 
educational/training video (e.g., a web-based video on the Mayo clinic website). Retraining was 
conducted periodically or as needed. 
 To control for avoidable inaccuracies, competent assessors were provided with specific 
written instructions that described the procedures for properly measuring BP. Although BP is 
inherently variable, a standardized method has been recommended to facilitate accuracy. The 
pressure accuracy of the automatic BP monitor has been calibrated to +3mmHg or 2% of the 
reading; this accuracy was confirmed using a mercury sphygmomanometer prior to its use. To 
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control for deviations in BP measurement, the room temperature, positioning of the arm, and 
background noise (i.e., in a quiet room) were held as consistent as possible. Individuals were 
asked to refrain from eating, bathing, exercise, alcohol, and caffeine or nicotine consumption for 
30 minutes prior to the assessment, as recommended in the instruction manual for the device due 
to their impact of BP readings. Prior to the assessment, individuals were also told that, as part of 
the standard method of measuring BP, he/she may be asked to remove clothing, or not wear 
clothing, that covers the upper arm where the cuff is typically placed. After 3-5 minutes of quiet 
rest by the individual, the assessor placed the appropriately sized BP cuff on the upper arm about 
½ above the elbow, and ensured that the tubing fell in the front center of the participant’s arm. 
Prior to and during BP measurement, participants were be asked to sit comfortably, legs 
uncrossed, and with the back and arm supported (i.e., muscle tension in the arm was discouraged 
by supporting it) so that the middle of the cuff of the upper arm was at the level of the right 
atrium (i.e., mid-point of the sternum). The participant was reminded to rest quietly and refrain 
from talking and/or moving during BP measurement. A BP reading was taken in both right and 
left arms initially (baseline only), and an additional two readings were taken in the arm with the 
higher reading (use same ‘highest” arm for following assessments). About 2-3 minute lapses 
were provided between measurements in the same arm. Average DBP and SBP were calculated 
for each arm (during baseline), and the arm with the higher average BP was used for 
posttreament and 3-month follow-up assessments. If the monitor did not record a reading (error, 
‘E’), the assessor repositioned the cuff and repeat the procedures for BP measurement, as is 
recommended in the instruction manual for the device. 
2.6.2. Social problem-solving ability: Social Problem-Solving Inventory-Revised: Short-Form: 
(SPSI-R:SF; D’Zurilla, Nezu, & Maydeu-Olivares, 2002). This is the short, 25-item version of 
 25	  
the SPSI-R, which was derived from a factor analysis of the original theory-driven Social 
Problem-Solving Inventory (SPSI) developed by D’Zurilla and Nezu (1990). It measures SPS 
ability and is comprised of five scales: (a) positive problem orientation (view problems as 
challenges and as solvable, maintain good self-efficacy, accept problems as part of life, 
understand that problems take time and effort to solve) (b) negative problem orientation (view 
problem as threats and unsolvable, doubt one’s ability to cope successfully with problems, 
become frustrated and upset when facing problems or negative emotions), (c) rational problem 
solving (planful attempts to cope with stressful problems), (d) impulsivity/carelessness style 
(tendency to engage in impulsive, hurried or incomplete attempts to solve problems), and (e) 
avoidance style (tendency to avoid problems, procrastinate, and depend on others to solve 
problems). The inventory provides both a total score of SPS ability and single scores for each of 
the five SPS scales. Higher scores on a given scale indicate higher levels of that particular 
dimension. Research suggests that the SPSI-R contains strong psychometric properties (i.e., 
internal consistency of α = 0.79 to 0.95 across scales, test-retest reliability for the total score 
ranging from 0.89 to 0.93, and evidence of strong structural, concurrent, predictive, convergent 
and discriminant validity according to D’Zurilla and colleagues, 2002).  
2.6.3. Stress: Perceived Stress Scale (PSS; Cohen, Kamarck, & Mermelstein, 1983). This widely 
used, valid and reliable measure of one’s perception of stress and the degree to which situations 
in one’s life are appraised as unpredictable, uncontrollable, and overloaded. It consists of ten 
items and uses a self-report format. Items and the response scale, ranging from never to very 
often, are easy to understand and the measure typically takes about five minutes to complete. 
Questions on the PSS asked about feelings and thoughts during the last month and respondents 
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rate how often they’ve felt a certain way. Perceived stress has been shown to influence high BP, 
and this commonly used measure served as a means of assessing it. 
2.6.4. Quality of life: Short Form Health Survey, Version 2 (SF-12v2; Ware, Kosinski, & Keller, 
1996). This general, standardized health-based survey instrument consists of 12 items extracted 
from the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36). This brief 
measure typically takes about two to three minutes to complete. The SF-12 is considered to be a 
valid and reliable assessment (e.g., Jenkinson et al., 1997; Ware, Kosinski, & Keller, 1996; Ware, 
Koslinki, Turner-Bowker, & Gandek, 2002). The measure assesses health-related quality of life 
(HRQOL) using eight scales that represent various health-related concepts (i.e., physical 
functioning, role limitations because of physical health problems, bodily pain, social functioning, 
general mental health, role limitations because of emotional problems, vitality and general health 
perceptions). The measure contains two summary scales, the physical component summary 
(PCS) and the mental component summary (MCS), representing physical health and mental 
health, respectively, both of which had reliability scores above 0.80 (Ware et al., 2002). Using 
scoring software by QualityMetric Incorporated, summary measures of mental and physical 
health are generated by aggregating information from the eight health domain scales, then 
recoding and transforming z and T scores on a 0-100 scale (Ware et al, 2010). Higher scores 
suggest better HRQOL, a T score 45 or greater represents average overall functioning in that 
dimension, and a 1 standard deviation below the mean indicates impaired functioning (Ware et 
al., 2010). This measure was included given the importance of HRQOL in general, and the 
finding of slightly poorer HRQOL for those with high BP compared to those without it (Trevisol, 
Moreira, Kerkhoff, Fuchs, & Fuchs, 2011).  
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2.6.5. Depression: Patient Health Questionnaire, Nine-item (PHQ-9; Spitzer, Kroenke & 
Williams, 1999). This is a brief, self-rated depression screening device adapted from the PRIME-
ME TODAY and utilized across various medical conditions, including CVD (e.g., Kroenke, 
Spitzer, Williams, & Löwe, 2010; Spitzer et al., 1994). The PHQ-9 can be used as either a 
diagnostic algorithm for making a probable diagnosis of major depressive disorder (MDD) or as 
a continuous measure, with scores ranging from 0 to 27 (Kroenke et al., 2010). Responses range 
from “not at all = 0” to “nearly every day = 3;” cut points of 5, 10, 15, and 20 represent mild, 
moderate, moderately severe, and severe levels of depressive symptoms (Kroenke et al., 2010). 
A probable diagnosis of MDD may be considered if one of the first two symptoms (i.e., 
depressed mood or loss of interest) is endorsed and a respondent endorses at least five of nine 
symptoms as present “more than half the days” (the ninth item is counted is “several days” is 
endorsed; Kroenke et al., 2010). The PHQ-9 has been found be valid and reliable, as indicated by 
criterion validity and reliability estimates generally above 0.80; the PHQ-9 is sensitive to change 
and has been well-validated for detecting and monitoring depression (Kroenke et al., 2010). A 
five-point decline in the score is considered representative of a clinical significant improvement 
(Kroenke et al., 2010).  Given the impact of depression on high BP and further health sequelae, 
this measure served as a means of exploring symptoms of depression as they relate to high BP.  
2.6.6. Adherence: Eight-Item Medication Adherence Scale (MMAS-8; Morisky, Ang, Krousel-
Wood, & Ward, 2008). This short self-report instrument was be used to measure adherence to 
(antihypertensive) medication. Morisky and colleagues (2008) employed primarily low-income, 
minority patients with hypertension and found this measure to be valid (i.e., good concurrent and 
predictive validity), reliable (α = 0.83) and scores significantly associated with BP control (p < 
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0.05). Medication adherence is a common barrier to high BP control, and was therefore 
important to assess. 
2.6.7. Lifestyle behaviors: A self-report questionnaire was developed to gather basic information 
about participants’ lifestyle behaviors generally, including diet, exercise, tobacco use, and 
alcohol consumption. Data gathered by the questionnaire served to determine differences 
between conditions on health behaviors that impact BP. The lifestyle behaviors questionnaire 
was intentionally brief, as compared to the use of standard comprehensive measures of health 
behaviors, to minimize participant burden. Items were based on empirically supported factors 
that impact BP. 
 In consideration of the time required a complete comprehensive measure of diet (e.g., the 
Food Frequency Questionnaire, which takes about 30 minutes to complete), and because diet was 
not a primary variable of interest, five items based on the Dietary Approaches to Stop 
Hypertension (DASH) recommendations were included in the lifestyle behavior questionnaire 
(Willett, 1998). Participants were asked to provide a response (i.e., “yes,” “no,” or “I don’t 
know”) to questions about whether they followed a DASH diet, both overall and specific to key 
eating recommendations (e.g., “Do you eat foods low in saturated fat, cholesterol and total fat?”). 
Note, for simplification, the questions did not contain specific information, such as servings or 
food content; therefore, the responses are limited to a self-reported general determination of a 
diet consistent with DASH. 
 Physical activity affects the ability of the heart to pump blood; regular physical activity 
allows the heart to pump more blood with less effort, resulting in less force against the arteries, 
thereby lowering BP (Simons-Morton, 2008). Participants were asked to report on the intensity 
of their physical activity, the frequency by which they engaged in at least thirty minutes of 
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physical activity (e.g., brisk walking), and how they would describe their activity level (i.e., 
vigorously, moderately, or seldom active). These questions were intended to assess the 
participant’s physical activity in general and in comparison to recommendations for physical 
activity in adults by the American Heart Association (Eckel et al., 2014). 
 Tobacco use was measured because it affects BP by damaging arteries and increases risk 
of atherosclerosis, in addition to temporarily increasing BP (e.g., Mukamal, 2006). Participants 
were asked if they currently use tobacco products, how many tobacco products they smoke per 
day, and how soon after waking they use their first tobacco product. 
 Heavy consumption has been associated with hypertension, a link with several possible 
mechanisms (Husain, Ansari, & Ferder, 2014; Miller et al., 2005; Puddey & Beilin, 2006). Self-
reported alcoholic beverage intake (e.g., average drinks per week, and number of alcohol binges 
per year) was measured (National Institute on Alcohol Abuse and Alcoholism, 2005). 
2.6.8. Program Evaluation: This questionnaire was created to obtain feedback on participants’ 
satisfaction with PST. Participants were asked to rate agreement with statements using a 5-point 
Likert scale, ranging from completely disagree (1) to completely agree (5). Items on the 
questionnaire were geared towards perceived credibility, effectiveness, and confidence in 
recommending the program to other patients with high BP. 
2.6.9. Data Collection: Prior to the baseline assessment, potential participants were instructed to 
refrain from caffeine, alcohol or nicotine intake, eating or exercise at least 30 minutes prior to 
being assessed. Assessments were completed at timepoint 1, hereafter referred to as “baseline,” 
timepoint 2, referred to as “posttreatment” (i.e., after eight sessions, about 8 weeks), and 3-month 
follow up (i.e., about three months after posttreatment assessment).  
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Assessors were masked to the treatment condition of the individual being assessed until 
after the assessment was completed. Those conducting the assessments were trained in 
standardized procedures for performing assessments validly and reliably. Assessors were 
instructed to follow a written protocol of assessment procedures. 
 When this study commenced, PST sessions were intended to be audio-recorded for 
quality assurance, with the participant’s permission. Two evaluators were expected to 
independently rate treatment integrity (i.e., competence and adherence) for 15% of randomly 
selected sessions. Refusal to grant permission did not exclude an individual from participation in 
the study, and efforts were made to inform participants about confidentiality and address 
concerns. During this study, five of the six participants in PST were asked for permission (one 
was not due to error), two patients provided permission (with the same therapist) and the other 
three denied permission. Special attention was not initially devoted to the standardization or 
rehearsal of requesting permission, but given the authorization rate of 33.33%, a script for future 
use was developed in which the rational and confidentiality of recordings were emphasized. 
 Participants were asked to complete a brief questionnaire containing items that targeted 
comprehension, utilization, and credibility of the treatment. These forms were respondent 
friendly, easy to understand, and brief (i.e., less than 5 questions each in a checkbox format). 
2.7. Research Design 
2.7.1. Experimental Manipulation: This investigation was developed as a two (condition) by 
three (time) mixed factorial design. Participants were randomly allocated to the treatment 
condition (i.e., PST or ETAU). Assessments were completed at three timepoints (i.e., baseline, 
posttreatment, and 3-month follow up). 
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2.7.2. Problem-Solving Therapy (PST): In the PST condition, a manualized PST protocol 
adapted to this patient population was implemented. This protocol was derived from PST, the 
evidence-based psychosocial intervention that promotes the adoption and effective application of 
adaptive problem-solving attitudes and skills to solve stressful problems in everyday living 
(D’Zurilla & Nezu, 2007; Nezu, 2004). Based on recent revisions and updates by Nezu and Nezu 
(2012) and Nezu, Nezu, and D’Zurilla (2013), the PST intervention contained four “toolkits”: (a) 
problem-solving multitasking (i.e., externalization, visualization, and simplification), (b) the 
“Stop, Slow Down, Think, and Act” (SSTA) method of approaching problems (i.e., emotional 
mindfulness and modulation), (c) healthy thinking and imagery (i.e., cognitive change techniques 
geared toward enhancing optimism self-efficacy and visualization to enhance motivation and 
decrease hopelessness), and (d) rational (or planful) problem solving (i.e., problem definition, 
generation of alternatives, decision making, and solution implementation and verification). 
Principles of SPS were integrated throughout treatment. The general PST protocol was adapted 
for a hypertensive population. The intervention contained strategies for delivering a culturally 
sensitive treatment (e.g., recognition of cultural values, previous discrimination, and the 
importance of family). 
 The intervention was conducted using an individual format. Treatment manuals were 
detailed and user-friendly (Appendix B). Advanced clinical psychology graduate students served 
as therapists. Each therapist provided the PST intervention to no more than four individuals at a 
given time. PST interventionists received at least eight hours of training in PST by treatment 
developers and experts in PST, Arthur M. Nezu, Ph.D., ABPP and Christine Maguth Nezu, Ph.D., 
ABPP. Christine Maguth Nezu, Ph.D., ABPP, a licensed clinical psychologist provided weekly 
clinical supervision for study therapists. Graduate student interventionists practiced delivering 
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PST with an individual who was not randomized, and whose data was therefore not analyzed. 
These ‘practice patients’ were not used for the ETAU condition, given the educational nature of 
the condition, as well as the structure (i.e., a script and invitation to ask questions) and brevity of 
the content. The purpose of this was to familiarize the interventionist with the protocol in a real 
setting, rather than training or role-play exercise, to reduce errors in the protocol and intervention 
delivery. It is notable that, of the five practice patients, three did not complete treatment; reasons 
for dropout included scheduling conflicts, and problems with transportation. 
  Individual sessions were delivered in an office conveniently located proximal to the 
medical clinic from which participants were referred. Individual treatment sessions were 
intended to be held approximately weekly for about eight weeks and last approximately sixty 
minutes in duration. 
2.7.3. Enhanced Treatment as Usual (ETAU): This condition served as the control condition and 
was enhanced with patient-friendly educational materials regarding high BP (i.e., a compilation 
of patient materials on the DASH eating plan and other materials developed by the National 
Heart, Lung, and Blood Institute and other health organizations).  
The ETAU condition entailed a manualized weekly telephone check-in to address 
questions about the delivered educational materials. Efforts were made to culturally adapt the 
content of this condition (e.g., culturally-sensitive examples). Patient-friendly educational 
materials consisted of information about high BP and guidance for lowering BP (e.g., steps to 
controlling high BP and recipes for heart health). Participants were asked to read a section for 
homework, typically one to three pages of information in the handbook. 
Once randomized to this condition, participants received a handbook of patient-friendly 
educational materials (e.g., materials developed by governmental agencies to promote BP 
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control). A weekly session was performed via the telephone using a written script and protocol. 
Trained graduate students reviewed the materials, which included strategies for reducing high BP 
and an opportunity to ask questions about the information delivered. A standardized manual for 
delivering health education to participants was provided to interventionists. The weekly sessions 
were conducted over the telephone during a time convenient to the participant, preferably at a 
time and location with limited distraction. A patient-friendly handbook was given to each 
participant after he/ she was randomization to the ETAU condition. The frequency of sessions 
was intended to be about once per week and duration was estimated to be about 30 minutes.   
2.8. Ethical considerations 
2.8.1. Confidentiality: Confidential and its limits were discussed with potential participants as 
part of informed consent, in accordance with APA standards and IRB regulation (American 
Psychological Association, 2010; Drexel University, 2015). Data was physically and 
electronically locked and password-protected, respectively. All study personnel received training 
on data security and confidentiality. In compliance with the Drexel University Investigator 
Manual (2015), research records are kept for at least three years after completion of research. 
2.8.2. Diversity: Given the health disparities affecting African Americans, as well as the high 
prevalence rates of high BP among African Americans and the expected predominance of this 
ethnic minority in the sample, it was important to tailor recruitment and treatments to this 
population. Informed by past research, drawing interest in participation from Black individuals 
during recruitment and providing culturally sensitive treatments were addressed through assessor 
and interventionist trainings (e.g., conveying respect in the delivery of treatment, understanding 
the important of family in this population), advertisements and manuals that included culture-
specific preferences (e.g., depicting Black individuals engaging in health behaviors, recognizing 
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the structure and value of families in treatment examples), explaining the potential direct and 
indirect benefits of participation, being flexible in scheduling assessments and treatment sessions 
for participant convenience, and providing compensation, though only a small amount due to 
budget constraints (Lukoschek, 2003; Yancey et al., 2006).  
2.8.3. Safety: There were no adverse events to report to the IRB according to its policies (Drexel 
University, 2015). Documentation of circumstances in which concerns for safety arose (e.g., 
dangerously high BP) was kept with other locked study documents. 
Training in suicide risk assessment and the safety protocol was established in case a 
response greater than “0” on item number 9 of the PHQ-9 (i.e., “thoughts that you would be 
better off dead, or of hurting yourself” with a frequency greater than “not at all”) was provided 
during an assessment, or if indication of suicidal ideation, intent or plan was verbally stated or 
otherwise perceived by interventionists and/or supervisors. The suicide safety protocol included 
instructions for contacting a clinical supervisor, providing telephone numbers for those in crisis, 
and, if deemed appropriate (i.e., high risk), escorting the participant to the nearest emergency 
room and alerting pertinent personnel. 
A protocol for responding to dangerously high BP during an assessment was established 
and training was provided to study personnel. After consultation with a collaborating physician, 
dangerously high BP was operationally defined as a SBP reading ≥ 180 mmHg or DBP reading ≥ 
110 mmHg (Chobanian et al., 2003). In cases of dangerously high BP during an assessment, 
participants were asked to contact his/ her physician directly or provide permission for the 
assessor to contact the participant’s physician or a physician consulting on the study, or be 
willing to be escorted to the nearest emergency room. 
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2.8.4. Reporting: Reports derived from this study comply with Journal Article Reporting 
Standards (American Psychological Association Publications and Communications Board 
Working Group, 2008). 
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CHAPTER 3: RESULTS 
3.1. Statistical Analyses: Analyses were performed using SPSS Version 22 software. Outlined 
hypotheses were determined a-priori, but planned analyses were necessarily modified due to 
small sample size, few participants with completed 3-month follow up assessment due to timing 
of analyses, as well as the distribution and dispersion of variables. The preferred method of 
testing this two-by-two (treatment-by-time) mixed factorial design was repeated-measures 
Analysis of Variance (RM ANOVA) with assessment point (baseline and posttreatment) as the 
within-participants variable and treatment condition (ETAU versus PST) as the between-
participants variable. When homogeneity of variance was violated, as indicated by a statistically 
significant Levene’s test, the best alternative was determined to be an independent samples t-test 
using change scores (i.e., baseline scores subtracted from posttreatment scores to account for 
change over time). Effect sizes were estimated and described as small, medium or large 
according to the standards set forth by Cohen (1992). In consideration of the inflation of type I 
error due to multiple tests, a conservative Bonferroni correction was considered for t-tests and 
the more powerful Sidek correction for ANOVAs, although no inferential tests yielded 
statistically significant results for interaction effects at p < 0.05 (Fields, 2005). Due to the 
influence of low sample size on power to detect statistical significant, effect size are of primary 
interest. Table 3 contains the means and standard deviations for each condition at baseline and 
posttreatment, as well as the results of t-tests and estimated effects sizes for outcome variables in 
which change scores were used. Table 4 contains means and standard deviations for each 
condition at baseline and posttreatment, as well as the F-ratio, level of statistically significance, 
and effect size estimate (i.e., partial eta-squared) for outcome variables in which a RM ANOVA 
was conducted. 
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3.1.1. Missing data: Efforts to minimize attrition were made (e.g., compensation for time and 
travel, flexibility in scheduling sessions and phone call appointment reminders). Intent-to-treat 
analysis was used to minimize the effects of attrition on study findings; however, imputation was 
used only for participants who initiated treatment (i.e., a dropout was operationally defined as a 
participant who ceased treatment after the first session) rather than any participant who was 
randomized. Although not superior to multiple imputation, means imputation was used rather 
than last observation carried forward (LOFC), in consideration of the effects of time on outcome 
variables. For other missing data, imputation was used in accordance with guidelines provided 
for each measure, most frequently the mean of a given scale or subscale of that case. Two cases, 
one randomized to each condition, were excluded from analyses. One case randomly assigned to 
the ETAU condition dropped out of the study after 2 sessions due to “family issues;” for this 
case, the ETAU means across variables at posttreatment were imputed as part of intent-to-treat 
(ITT) analyses (Ntotal = 12, nETAU = 6, nPST = 6). 
3.1.2. Assumptions of statistical tests: Prior to conducting analyses, the distributions of variables 
within each condition were inspected to determine whether assumptions of parametric tests were 
met, including normality, lack of significant outliers, and homogeneity of variance using 
descriptive statistics, graphical representations of data and established tests (e.g., Fields, 2009). 
The Shapiro-Wilk test indicated that the distribution of DBP was non-normal, as were the 
distributions of a few demographic variables and health behavior variables. Transformations 
were used for distributions that were non-normal and contained outliers.  
3.1.3. Determination of covariates: Baseline data were examined for between-condition 
differences using t-tests with equal variance not assumed for variables yielding a significant 
Levene’s test, the nonparametric Mann-Whitney U for non-normally distributed continuous 
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variables, Pearson’s Chi-Square test for categorical variables, or Fisher’s Exact when the 
expected cell count was less than five. As expected with random assignment, there were no 
statistically significant between-condition differences across variables at baseline. 
3.1.4. Preliminary efficacy: A major objective of this study was to determine the preliminary 
efficacy of PST as compared to ETAU, in patients with high BP. A series of hypotheses extend 
from this aim, as discussed below; these include evaluating changes in SBP and DBP, SPS 
ability, medication adherence, mental and physical HRQOL, and depressive symptoms between 
treatment conditions from baseline to posttreatment. 
A change/ gain score approach was used to examine the mean differences in SBP 
between ETAU and PST from baseline to posttreatment, rather than the preferred mixed RM 
ANOVA, because the assumption of homogeneity of variance was violated (i.e., Levene’s test 
indicated that variances between conditions were statistically significantly different at 
posttreatment). On average, participants in both the ETAU (M = -8.27, SD = 15.87) and PST (M 
= -10.11, SD = 9.34) conditions showed reductions in SBP from baseline to posttreatment but the 
mean differences between conditions over time were not statistically significant [t(10) = 0.25, p 
= 0.81], and the effect size (d = 0.14) was small. As would be expected given the small sample 
size, the 95% confidence interval was large (-14.91 to 18.59), indicating the estimate of the 
population mean was not precise.  
The distribution of baseline DBP was non-normal, and transformations did not 
significantly improve normality; therefore, a change/ gain score approach was employed to 
examine mean differences in DBP between conditions from baseline to posttreatment. On 
average, participants in both the ETAU (M = -7.73, SD = 11.77) and PST (M = -1.61, SD = 9.31) 
conditions showed reductions in DBP from baseline to posttreatment. The difference between 
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mean change scores of the two conditions was not statistically significant [t(10)= 0.99, p = 0.34, 
95% CI = -19.77 to 7.53), so the null hypothesis was not rejected. Results indicated a medium-
sized effect (d = 0.58) of ETAU compared to PST. 
To test the hypothesis that the PST condition would have statistically significant 
improvements in SPS ability, compared to ETAU, from baseline to posttreatment, a RM 
ANOVA was used. Results showed a large main effect of time that was not statistically 
significant [F (1, 10) = 3.74, p = 0.08, ηp2 = 0.27]. The interaction of time and condition on SPS 
ability was also not statistically significant [F (1, 10) = 0.02, p = 0.89]. The magnitude of the 
difference between conditions (ηp2 = 0.002) indicated a trivial 0.2% of the variance in SPSI-R: 
SF scores accounted for by treatment condition. 
 A RM ANOVA showed a main effect of time that was not statistically significant, with a 
very small effect size [F (1, 10) = 0.004, p = 0.950, ηp2 < 0.001]. An examination of the time-
by-treatment interaction showed a large effect of PST compared to ETAU [F (1, 10) = 2.54; p = 
0.14; ηp2 = 0.20]. Figure 3 illustrates the increase in average medication adherence over time for 
those in the PST condition, while those in the ETAU condition decreased in adherence. 
  Due to a violation of homogeneity of variance according to Levene’s test, a change/ gain 
score approach was utilized to examine mean differences in mental HRQOL between conditions 
across timepoints. Contrary to the stated hypothesis, no statistically significant differences were 
found between conditions [t(6.40)= 1.14, p = 0.30, 95% CI = -6.69 to 18.72)] and those in the 
ETAU condition showed greater improvements (medium effect, d = 0.66) in mental HRQOL. 
  To test the hypothesis that the PST condition would show statistically significant 
improvements in the physical dimension of HRQOL, compared to ETAU, a RM ANOVA was 
used. Results for the main effect of time were not significant and the magnitude of the effect was 
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small [F (1, 10) = 0.27, p = 0.61, ηp2 = 0.03]. The time-by-condition interaction indicated that, 
on average, physical HRQOL of those in the ETAU decreased over time, whereas those in the 
PST condition showed improvement in physical HRQOL that was large in magnitude (F(1,10) = 
2.54, p = 0.14, ηp2 = 0.20; Figure 4). 
 A RM ANOVA yielded a statistically significant main effect of time on perceived stress 
[F (1, 10) = 12.303, p = 0.006], with a large effect size (ηp2 = 0.55). The interaction of time and 
treatment condition did not show a statistically significant effect [F (1, 10) = 0.25; p = 0.63], and 
the effect size that was revealed was small (ηp2 = 0.03). 
To test the hypothesis that the PST condition would demonstrate statistically significant 
improvements in depression from baseline to posttreatment, compared to ETAU, a RM ANOVA 
was used. Results suggested a main effect that was large in magnitude, but not statistically 
significant [F (1, 10) = 2.21, p = 0.17, ηp2 = 0.18]. The interaction of time and condition on 
depression was not statistically significant               [F (1, 10) = 0.05, p = 0.82, ηp2 = 0.005]. 
3.1.5. Feasibility: This aim examined the feasibility of conducting an RCT in this population as 
the study is designed, which includes the acceptability of the treatments by patients with 
uncontrolled high BP. Figure 2 shows the flow of participants according to JARS. 
 It was hypothesized that 80% of participants would be retained in treatment, as defined as 
having attended at least 6 sessions of PST or ETAU (i.e., an attrition rate of 20% or less). 
Completion was constituted by a minimum of 6 sessions. The completion rate of participants in 
the PST was 100% for those who initiated PST and 85.7% for those who were randomized to 
PST. For the ETAU condition, the rate of completion was 83.3% for those who initiated 
treatment (one participant dropped out after 2 sessions due to stated “family issues”) and 71.4% 
of those who were randomized to ETAU. Of particular interest, the high completion rate of PST 
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was consistent with other studies involving PST. Of note, attempts were made to contact the two 
participants who were randomized but never initiated treatment to ascertain reasons for not 
showing to a first session; one patient was unable to be reached and the other was unable to 
attend after multiple attempts due to scheduling conflicts. 
 To determine the feasibility of delivering treatment over the course of eight weeks, data 
was collected on time number of days from session one to session eight. The average number of 
days to complete eight sessions of treatment was METAU = 55.40 (SD = 7.99) and MPST = 63.17 
(SD = 14.13). These averages indicate that it is feasible to conduct the treatment within eight to 
eleven weeks. Data collected on the time elapsed from session eight to posttreatment assessment 
was consistent with the estimated hypothesized for the PST condition, but not the ETAU 
condition [METAU = 16.00 days (SD = 10.08); MPST = 13.83 days (SD = 12.73). The average 
number of days from posttreatment assessment to 3-month follow up assessment was within the 
hypothesized range [METAU= 102.50 days (SD = 7.77); MPST = 100 days (SD= 2.65)]. Because of 
barriers to attendance (e.g., medical appointments, transportation, adequate funds, and family 
obligations) made it difficult to attend sessions on a consistent weekly basis, attempts were made 
to be flexible in scheduling treatment and assessment sessions. This led to slight adaptations to 
the preferred timing of treatment and assessment sessions, including one instance in which two 
treatment sessions were scheduled in one week to compensate for a missed session, as well as 
times when participants were seen on a biweekly basis for a brief period of time. 
 As hypothesized, the percentage of participants who found this treatment acceptable (i.e., 
average ratings of 4 out of 5 or higher on items targeting credibility, effectiveness and 
confidence in recommending the treatment) was about 80% (METAU= 80%; MPST = 83.3%). It 
should be noted that this estimate reflects the satisfaction of participants who completed a 
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posttreatment assessment, all of whom completed treatment, and does not capture the opinions of 
participants who did not received a first session or who dropped out prior to completion. 
3.1.6. Exploration of follow up: Only very limited 3-month follow-up data was available (nETAU 
= 4, nPST = 3); basic inspection of means and graphs seemed to indicate limited maintenance of 
treatment gains. For inferential testing and more valid comparison of treatments over time, it is 
necessary to gather more data. 
CHAPTER 4: DISCUSSION 
 High BP is present in an alarmingly high rate of adults in the U.S. (i.e., it affects 
approximately one in three adults), disproportionately impacts African Americans, is a major risk 
factor for heart disease and stroke, and costs the U.S. billions of dollars each year (Chobanian et 
al., 2003; IOM, 2010; Lloyd-Jones et al., 2010; Nwankwo, Yoon, Burt, & Gu, 2013; Roger et al., 
2012). Although high BP is preventable and modifiable, the prevalence of high BP continues to 
rise, and control remains relatively poor (IOM, 2010). Controlling high BP remains challenging, 
particularly in African Americans, due to a host of biological, environmental, and behavioral 
factors (Fuchs, 2011). Psychosocial factors, including chronic stress and health behaviors, have 
been recognized as important in the development and treatment of high BP, having both direct 
and indirect effects. However the evidence base for psychosocial treatments has largely been 
considered inadequate or inconsistent (Bosworth et al., 2011; Blumenthal, et al., 2002; IOM, 
2010; Linden, et al., 1996; Rainforth et al., 2007). 
There remains a need to establish an intervention that is effective in reducing high BP in 
the real world, particularly for African Americans. PST is an evidence-based CBT that promotes 
the adoption and effective application of adaptive problem-solving attitudes and skills for dealing 
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with stressful problems in living. Before examining the effectiveness of PST in this context, it 
was first necessary to conduct this pilot RCT to determine preliminary efficacy and feasibility. 
The current study investigated the preliminary efficacy and feasibility of a PST 
intervention compared to an educationally-based ETAU condition, aimed at reducing BP, stress, 
and depression, while improving SPS ability, HRQOL, medication adherence. Main objectives 
were twofold: compare the effects of PST and ETAU from baseline to posttreatment, and assess 
the feasibility of implementing a full scale RCT in a predominantly Black, urban outpatient 
medical population.  
4.1. Preliminary Findings: 
4.1.1. Efficacy: A series of hypotheses were tested to determine preliminary efficacy of PST 
compared to ETAU across biopsychosocial outcomes. No statistically significant time-by-
treatment interactions were found; this is not surprising given the small sample size (nETAU = 6, 
nPST = 6). Rather than focusing on statistically significant effects, attention was placed on the 
magnitude and clinical significance of effects. RM ANOVAs yielded a large effect of time on 
outcome for SPS ability, perceived stress, and depression. Although these effects are notable, 
with a number of possible explanations (e.g., improved health education; experimental artifact), 
the primary focus was on the efficacy of PST compared to ETAU and clinically significant 
changes in outcomes. 
Regarding blood pressure, participants showed reductions over time that were not 
statistically significant or differential between conditions; the main effect of time may be 
attributed to a number of factors, including treatment effects and medication effects. Those in the 
PST condition showed slight greater reductions in SBP on average, and those in the ETAU 
condition had greater reductions in DBP on average. A greater number participants (nPST = 4) in 
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the PST condition showed clinically significance reductions in SBP (i.e., ≥ 5mmHg) compared to 
the ETAU condition (nETAU = 2) and half of those in either condition show clinical reductions in 
DBP. The results provide small preliminary indication that PST may produce meaningful 
reductions in high BP; however, as discussed in the limitations sections, the generalizability of 
such findings is limited given the low sample size, as well as concerns about confounding 
variables (e.g., medication effects) and threats to validity and reliability.  
 Regarding medication adherence, results showed a trend toward greater efficacy of PST 
compared to ETAU (ηp2 = 0.20) and one participant in the PST condition showed a clinically 
significant improvement in medication adherence. Given the significant problem nonadherence 
poses to health outcomes, this finding highlights the potential value of PST. Medication 
adherence was not specifically targeted in the PST manual, but may have been identified by 
participants as a problem to target. It may be possible to amplify the effect of PST on medication 
adherence by standardizing it as a problem to target within the treatment. 
 PST and ETAU had differential effects on HRQOL compared to one another, with a 
greater effect of ETAU on the mental health component of HRQOL (d = 0.66), and a larger 
effect (ηp2 = 0.20) of PST shown on the physical component of quality of life. At first glance, 
given PST is an evidence-based mental health treatment, these findings were surprising; however, 
upon close inspection of the clinical significance of changes from baseline to posttreatment, the 
mental component summary data shows two participants from the PST condition showed 
clinically significant improvements compared to only one participant in the ETAU condition. 
These findings are consistent with literature supporting the benefits of PST on improving mental 
health. Of note, one participant in the PST condition showed a clinically significant decline in 
this dimension. In examining the physical component of HRQOL (e.g., physical functioning and 
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role limitations because of health problems), there was a trend towards greater improvement for 
those receiving PST; however, none of these changes represented clinical significance. 
  It was hypothesized that those in the PST condition would show greater improvement in 
SPS ability, perceived stress, and depression, given the cognitive-behavioral roots, clinical 
targets and evidentiary support of the PST related to these constructs. Surprisingly, there were 
virtually no meaningful differences between PST and ETAU across these variables. Possible 
explanations for the lack of mean differences include threats to validity, namely restricted range 
of scores (e.g., SPS ability generally fell in the normal range, depression scores were, on average 
in the minimal to mild range) and demand characteristics, compromised integrity of the treatment 
(e.g., an interventionist used PST unintentionally in the delivery of ETAU), and overlap between 
the treatments (e.g., both treatments use a problem-solving approach). Notably, one participant in 
the PST condition showed a clinically significant reduction in depression. 
 Overall, preliminary evidence, ranging in magnitude and type (i.e., efficacy versus 
clinical significance), suggest a possible trend toward the efficacy of PST for uncontrolled high 
BP. Specifically, compared to ETAU, PST showed a greater preliminary effects on SBP, 
medication adherence, physical functioning, SBP, as well as  a greater percentage of clinically 
significant improvements in mental HRQOL. This evidence is preliminary, with a number of 
limitations to consider; as such, it is necessary to further evaluate efficacy. 
4.1.2. Feasibility: Not only was it important to determine the preliminary efficacy of PST 
compared to ETAU, it was also imperative to assess whether conducting a larger RCT would be 
feasible, given real-world constraints (e.g., access to participants).  
 As shown in Figure 2, 13.0% (N = 14) of the 108 patients recruited across multiple 
medical outpatient clinics over about 20 months were enrolled; of those who did not enroll, 
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43.6% did not meet inclusion criteria, 4.3% were excluded, 25.5% refused to participate, and 
25.5% were unable to be fully assessed. The challenge of obtaining an adequate sample size is 
expected given the financial and environment constraints of an urban setting that serves 
primarily patients of low SES; with an awareness of such constraints, efforts were made to 
enhance recruitment, but these appeared insufficient. Perhaps prioritization of community 
outreach/ partnership (e.g., through already established university networks) or utilization of 
strategies effective in similarly difficult to enroll populations (e.g., motivational interviewing, 
health education) during recruitment would have improved enrollment. 
 Completion rates for both PST and ETAU indicated strong retention of participants once 
treatment was initiated; for participants who were randomized, the percentage was slightly lower, 
but still acceptable at about 20%. Treatment was completed in a reasonable timeframe, about 
eight to nine weeks and assessments were typically completed within three weeks of the 
expected time; this may have been impacted by efforts to make participation more accessible to 
patient’s including attempts were made to make both treatment sessions and assessment as 
convenient as possible, given barriers to attendance (e.g., medical appointments, transportation, 
adequate funds, and family obligations). Fidelity was not assessed due to a lack of adequate 
audio-recordings.  
The majority of participants who completed treatment rated it as acceptable in terms of 
credibility and effectiveness (i.e., greater than provided ratings ≥ 4 out of 5). Data on those who 
did not complete treatment is not available; therefore, this estimate is biased because it is 
unknown how acceptable the treatments were to all randomized participants. 
4.3. Limitations: Findings of this study must be interpreted with caution, as there are a number 
of factors that threaten validity and reliability. The limitations are expected when attempting to 
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conduct research in a real-world context, with its accompanying restraints (e.g., not using highly 
restrictive inclusion criteria, modest financial and practical resources). Analyses were performed 
with a small sample size insufficient in reflecting the population, although the demographic 
make-up does reflect the high rates of high BP among Black women. The small sample size 
negatively impacted the power to detect statistically significant differences, hence the primary 
focus on effect sizes. Involvement in the community, rather than medical outpatient clinics as a 
main source of recruitment, has been shown to assist in engaging minority populations and 
would likely increase the rate of participant accrual, though this was not feasible given a lack of 
adequate resources. This may be especially true for patients with high BP, in that many are 
unaware of the condition and have little education about its effects, so they may not seek medical 
care (Chobanian, et al., 2003). 
  The data collected thus far, and analyzed contained non-normal distributions, 
heterogeneous variance, and outliers, thereby violating assumptions of inferential tests and 
limiting the types of statistical analyses possible. Regression to the mean and measurement error 
(e.g., inaccurate BP readings) may have impacted changes scores, which were necessary to use 
for a few variables.  
  Although intent-to-treat analysis was used to minimize the effects of attrition on study 
findings, imputation was performed only on cases that were considered dropouts (i.e., 
participants who ceased treatment after at least one session) and two cases that were randomized 
but not considered dropouts were deleted. A single participant from each study condition did not 
attend a first session after random assignment (e.g., unable to be reached via telephone or mail 
after multiple attempts or unable to attend a first session via telephone or in person); therefore, 
two cases were excluded from analyses (see Figure 2). Because these participants were unable to 
 48	  
be reached, no data beyond baseline was collected. Although attrition was not differential 
between groups in this regard, it is unknown whether participants who did not attend a first 
session differ from those who attended at least one session, and as such, serves as another 
limitation generalizability of findings. 
  With the aim of evaluating feasibility, sampling was intentionally performed in the 
context of a real-world medical setting; thus, it was necessary to balance methodological ideals 
within a limiting real-world environment. Additionally, due to limited resources, the study 
sample was drawn from medical outpatient clinics in one urban hospital network, and consisted 
of patients who showed for appointments, volunteered to participate and had the resources to 
attend assessments and treatment sessions (e.g., access to transportation). The small amount of 
compensation was, in some cases, not enough to cover the cost of public transportation to attend 
the PST sessions.  
  Regarding BP in particular, a number of other factors may have influenced findings, 
such as unreported changes in medication, reliance on self-report (e.g., for medication 
adherence), and unmeasured factors (e.g., weight changes). The majority of patients referred to 
the study came from a hypertension clinic; medication was often prescribed or changed during 
the appointment. As such, it is possible that the effects of that medication occurred after baseline 
and before posttreatment, thereby confounding change observed over time. Although participants 
were asked to report changes in medication, it is possible that changes were not reported. 
4.4. Future Directions: This pilot investigation was the first randomized controlled trial to 
examine the efficacy and feasibility of PST compared to ETAU across various outcomes in a 
sample of individuals with uncontrolled high BP. There are a number of recommendations to 
improve the validity and generalizability of findings. First, continued data collection is needed to 
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increase the sample size, which should lead to more precise parameter estimates and the ability 
to use hierarchical modeling to examine effects longitudinally, including 3-month follow up data 
and mediators/ moderators of outcomes. Second, recruitment should be expanded to include 
community outreach in the form of building relationships with community leaders, creating a 
presence at community events/ activities (e.g., church services), and utilizing already established 
pathways between the university and the community. Third, increase compensation, if possible, 
and other means to reduce barriers to participation and increase interest. Fourth, examine weight 
as a possible covariate by measuring it at each assessment timepoint, given the association 
between weight loss and reductions in high BP (e.g., Brook et al., 2013; Harsha & Bray, 2008). 
Fifth, re-evaluate the device used to measure BP and consider an ambulatory blood pressure 
monitor, or other accurate methods, if funding is available. Sixth, examine fidelity in the delivery 
of PST; this may involve efforts to increase the likelihood of receiving permission to record 
sessions (e.g., as mentioned, a script for interventionists to use). Seventh, gather data from 
interventionists on the implementation of PST; this should include, for example, acceptability of 
the treatment, comprehension, ease of delivery, and feasibility given time restrictions. Eighth, 
conduct qualitative and quantitative analyses of participant utilization of PST strategies, 
including rate of homework completion, comprehension and utilization outside of and after 
treatment as well as preferences for treatment modality (e.g., in person, telephone, web-based 
options). Ninth, collect data from dropouts, if possible. And lastly, revise the PST treatment 
manual to be better adapted to patients with high BP after gather feedback from participants and 
interventionists on this (e.g., target specific problems like adhering to medication, meeting 
dietary restrictions). Given the preliminary trend towards the efficacy of PST, it is recommended 
that the aforementioned enhancements be used to further improve feasibility and evaluate PST 
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for reducing uncontrolled high BP and depression, and improving SPS ability, medication 
adherence, and HRQOL within a predominantly Black population.  
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APPENDIX A: Tables and Figures 
 
Table 1 
List of Measures at Each Timepoint, Range of Possible Scores, and Clinical Significance 
 Pre Post 3-mo. 
FU 
Estimate 
of Time 
(minutes) 
to 
Complete 
Range 
of 
Scores 
CS 
Descriptive Measures       
Demographics Form X   5   
Lifestyle Behaviors 
Questionnaire (LBQ) X X X 5  
 
Feasibility Measures       
Treatment Expectations/ 
Acceptability (completed 
after the first session) 
X X  5  
 
Outcome Measures       
Blood Pressure (mmHg) 
(average of 3 readings) X X X 10-20 0-299 
 
        Δ -5 
- Systolic Blood Pressure       
- Diastolic Blood 
Pressure      
 
Social Problem Solving 
Inventory- Revised: Short 
Form (SPSI-R: SF) 
X X X 10 0-20 
 
Morisky Medication 
Adherence Scale 
(MMAS-8) 
X X X 5 0-8 
 
Δ ≥2 
Short Form Health 
Survey 12 (SF-12) X X X 2-3 0-100 
 
±10 
- Mental Component 
Summary (MCS)      
 
- Physical Component 
Summary (PCS)      
 
Perceived Stress Scale 
(PSS) X X X 5-10 0-40 
 
Patient Health 
Questionnaire (PHQ-9) X X X 5 0-27 
≤9 and 
Δ -50% 
Note: Pre, baseline timepoint; Post, posttreatment timepoint; 3-mo. FU, 3-month  
follow-up timepoint; CS, clinical significance for that measure; Δ, change.
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Note: * denotes Ntotal=12, nETAU=6, nPST=6; ** denotes Ntotal=11, nETAU=5, nPST=6; *** denotes 
Ntotal=11, nETAU=6, nPST=5.
Table 2   
Characteristics of Sample- Self-Reported Socio-demographic Information 
Variable Category Mean (SD) or % (n) 
  Total ETAU      PST 
*Age (years) 58.6 (10.6) 56.2 (11.6) 61.0 (9.9) 
Sex Female 66.7% (8) 66.7% (4) 66.7% (4) 
 Male 33.3% (4) 33.3% (2) 33.3% (2) 
Race Black  75.0% (9) 66.7% (4) 83.3% (5) 
 White 16.7% (2) 33.3% (2)   0.0% (0) 
 Asian   8.3% (1)   0.0% (0) 16.7% (1) 
*Education (years) 14.2 (2.2) 13.7 (2.0) 14.7 (2.4) 
**Household Members  2.5 (1.6) 2.0 (0.7) 2.8 (2.1) 
Household < $20,000 41.7% (5) 33.3% (2) 50.0% (3) 
Income $20,000-$40,000   8.3% (1) 16.7% (1) 0.00% (0) 
 $40,000-$60,000 33.3% (4) 16.7% (1) 50.0% (3) 
 $60,000-$80,000   8.3% (1) 16.7% (1)   0.0% (0) 
 $80,000-$100,000   8.3% (1) 16.7% (1)   0.0% (0) 
Marital Status Divorced/ Separated 41.7% (5) 50.0% (3) 33.3% (2) 
 Single/ Never Married 33.3% (4) 16.7% (1) 50.0% (3) 
 Married/ Partnered 25.0% (3) 33.3% (3) 16.7% (1) 
Religious/  Yes 100% (12) 100% (12) 100% (12) 
Spiritual No   0.0% (0)   0.0% (0)   0.0% (0) 
Current  Working Full Time 33.3% (4) 33.3% (2) 33.3% (2) 
Job Status Retired 25.0% (3) 16.7% (1) 33.3% (2) 
 Disability/ Subsidy 25.0% (3) 33.3% (2) 16.7% (1) 
 Unemployed 16.7% (2) 16.7% (1) 16.7% (1) 
***Years since diagnosis 12.6 (9.2) 13.7 (9.8) 11.4 (9.4) 
>1 medical Yes 67.7% (8) 67.7% (4) 67.7% (4) 
comorbidity No 33.3% (4) 33.3% (2) 33.3% (2) 
>2 medical Yes 16.7% (2) 33.3% (2)    0.0% (0) 
comorbidities No 83.3% (10) 66.7% (4)  100% (6) 
Family History Yes 91.7% (11) 100% (6) 83.3% (5) 
of high BP No     8.3% (1)   0.0% (0) 16.7% (1) 
Treatment Yes 91.7% (11) 83.3% (5) 100% (6) 
Completer No    8.3% (1) 16.7% (1)    0.0% (0) 
**Medication  Yes 27.3% (3) 60.0% (3)    0.0% (0) 
Change during 
study 
No 72.7% (8) 40.0% (2)  100% (6) 
**Hospitalized Yes   9.1% (1)   0.0% (0)  16.7% (1) 
during study  No 90.9% (10)  100% (5)  83.3% (5) 
**Other Service  Yes 27.3% (3) 40.0% (2)  16.7% (1) 
during study No 72.7% (8) 60.0% (3)  83.3% (5) 
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Note: ETAU, enhanced treatment as usual; PST, Problem-Solving Therapy; Pre, baseline 
timepoint; Post, posttreatment timepoint. 
a df  = 10 
b df  = 6.40
Table 3 
Means ±SDs for ETAU and PST at Baseline and Posttreatment, and t-Test Results and 
Effect Sizes using Change Scores 
 ETAU Mean ± SD PST Mean ± SD    
Measure Pre Post Pre Post t  p Cohen’s d 
        
SBP  153.61 
±17.29 
143.07 
± 8.93 
162.11 
±22.17 
152.00 
±21.99 0.25 
a 0.81 0.14 
DBP 88.56 
±9.67 
81.74 
±8.25 
93.83 
±6.77 
92.22 
±15.26 0.99 
a 0.34 0.58 
SF12MCS 45.49 
±3.73 
51.96 
±4.25 
47.38 
±9.06 
47.87 
±12.85 1.14 
b 0.30 0.66 
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Note: ETAU, enhanced treatment as usual; PST, Problem-Solving Therapy; Pre, baseline 
timepoint; Post, posttreatment timepoint. 	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Table 4 
Means ±SDs for ETAU and PST at Baseline and Posttreatment, and Time-by-Treatment 
Interactions with Effect Size Estimates using RM ANOVA 
 ETAU Mean ± SD PST Mean ± SD    
Measure Pre Post Pre Post F (1, 10) p ηp2 
        
SPSI-R 14.57 
±3.33 
15.83 
±3.43 
13.57 
±1.33 
14.66 
±2.20 0.02 0.89 0.002 
MMAS 6.04 
±1.86 
5.50 
±2.14 
6.25   
±1.20 
6.75 
±1.57 2.54 0.14 0.20 
SF12PCS 46.04 
±10.20 
42.14 
±8.80 
37.67 
±10.31 
39.66 
±11.56 2.54 0.14 0.20 
PSS 19.33  
±3.50 
13.20 
±6.24 
19.33 
±5.28 
14.50 
±7.15 0.25 0.63 0.03 
PHQ-9 5.00 
±2.76 
4.40 
±4.08 
8.50 
±7.99 
5.50 
±7.69 0.05 0.82 0.005 
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Figure 1 	  	  	  
Hypothesized model of social problem solving in relation to distress, health behaviors, and 
medical disease among patients with high BP. 
Life%Stress%(e.g.,&family&
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responsibili7es,&&
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Figure 2 
 
 
 
JARS Participant Flow Diagram	  
 
	  
 
Assessed for 
eligibility (n=108) 
Analyzed baseline to posttreatment 
(n=6) 
• Excluded from analysis (n=1) 
Received full program (n=6) 
• Lost to posttreatment (n=0) 
• Discontinued intervention (n=0) 
Assigned to PST (n=7) 
• Received experimental intervention 
(n=6) 
• Did not receive experimental 
intervention (n=1, unable to reach after 
baseline) 
Received full program (n=5) 
• Lost to posttreatment (n=0) 
• Discontinued intervention (n=1 
after session 2 due to family issues) 
Assigned to intervention ETAU (n=7) 
• Received comparison intervention (n=6) 
• Did not receive comparison intervention 
(n=1 unable to schedule next session 
due to problems with telephone) 
Analyzed baseline to posttreatment 
(ITT n=6) 
• Excluded from analysis (n=1) 	  
Allocation 
Analysis 
Posttreatment 
Assignment (n=14) 
Enrollment 
Completed (n=3); (2 due for FU) 
• Lost to follow-up (n=1, unable 
to reach) 
• Discontinued intervention (n=0) 
 
Completed (n=4); (1 due for FU) 
• Lost to follow-up (n=0) 
• Discontinued intervention (n=0) 
 
3-month FU 
Excluded  (total N=94): 
• Did not meet inclusion criteria 
(n=41, includes BP 
controlled=5) 
• Excluded (n=4; includes 
receiving other therapies=3, 
unstable psychiatric 
medication=1) 
• Refused to participate (n=24; 
includes not interested=11, 
time commitment=6, travel=4, 
compensation inadequate=3) 
• Other (n=25; includes 
incomplete screen within 3 
mos.=24; eligible but unable to 
contact=1) 
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Figure 3 
 
 
 
Interaction of Time and Condition on Medication Adherence 
 
 
Note: MMAS, Morisky Medication Adherence Scale; ETAU, enhanced treatment as usual; PST, 
Problem-Solving Therapy; Pre, baseline timepoint; Post, posttreatment timepoint. 	  	  	  	  	  	  	  	  
0 
1 
2 
3 
4 
5 
6 
7 
8 
Pre Post 
M
ed
ic
at
io
n 
A
dh
er
en
ce
 
Assessment Timepoint 
Time-by-Treatment on MMAS 
ETAU 
PST 
Figure 4 
 
 
 
Interaction of Time and Condition on Physical HRQOL 
 
 
Note: SF-12 PCS, Short Form Health Survey Physical Component Summary; ETAU, enhanced 
treatment as usual; PST, Problem-Solving Therapy; Pre, baseline timepoint; Post, posttreatment 
timepoint. 
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APPENDIX B: Intervention Manual Outlines 
PST Treatment Manual Session Outline 
Session 1:  
• Introduction to the program and the therapist 
• Education about the relationship between stress and HBP 
• Education about problem solving as a mediator of stress and HBP; PST as a coping 
mechanism to effectively manage stress 
• Education about PST 
• Evaluation of SPS abilities 
 
Sessions 2-6:  
• Brief review of PST-HBP 
• Guided practice of PST-HBP applied to current stressful problems 
• Training in multi-tasking tools for cognitive overload (i.e., externalize, visualize 
simplify), the S-S-T-A method for overcoming emotion dysregulation (i.e., stop, slow 
down, think, act), healthy thinking and positive imagery for overcoming negative 
thinking (i.e., ABC model of thinking, healthy thinking rules), and planful problem-
solving skills (i.e., define the problem, generating alternatives, decision making, action 
plan) 
 
Session 7-8:  
• Review of PST-HBP 
• Forecast possible future problems 
• Teach the use of PST skills as a means of preventing increased levels of stress 
• Wrap-up 
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ETAU Treatment Manual Session Outline 
Session 1:  
• Introduction to the program and the therapist 
• Orientation to the patient handbook 
 
Sessions 2-7:  
• What is High Blood Pressure? 
• What Causes High Blood Pressure? 
• Why is High Blood Pressure Bad? 
• Lifestyle Changes Can Help Reduce your HBP 
• Healthy Weight 
• Eating Right 
• Being Active 
• Blood Pressure Medications 
• Quit Smoking 
• Chronic Stress and the Heart 
• DASH details 
•  
Session 8:  
• Ask your Doctor 
• Wrap-up 
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APPENDIX C: Consent Form 
1. Title of research study: A Pilot Randomized Controlled Trial Comparing the Efficacy of 
Problem Solving Therapy to Enhanced Treatment as Usual for Reducing High Blood Pressure, 
Protocol #1206001351 
 
2. Researcher: Arthur M. Nezu, Ph.D., ABPP 
 
3. Why you are being invited to take part in a research study 
We invite you to take part in a research study because: 
• You have presented with persistently high blood pressure or have a current diagnosis of 
hypertension given or confirmed by a board certified physician 
• You have uncontrolled high blood pressure 
• You are between 18-75 years old 
• You are willing to give us permission to obtain information regarding your medical 
history as it pertains to any current or previous cardiovascular problems or related 
diseases 
• You are able to read and understand this consent form 
• You are not be in a current state of decompensated heart failure or a diagnosis of heart 
failure requiring inotrope agents 
• You are not be currently receiving chemotherapy, radiation therapy, or dialysis 
• You have not had a heart attack/ myocardial infarction in the previous six months 
• You are not currently pregnant or planning to become pregnant within six months of 
treatment initiation 
• You have not been hospitalized in the past two months for hypertension-related or 
psychiatric reasons 
• You are not currently receiving psychotherapy/counseling 
• You are not currently taking psychotropic medication that may impact outcomes (e.g., 
depression) without stable dosage and/or with planned change in dosage within six 
months of treatment initiation. Psychotropic medications are medications that have been 
prescribed by a physician to treat a diagnosed mental health disorder. 
 
4. What you should know about a research study 
• Someone will explain this research study to you. 
• Whether or not you take part is up to you. 
• You can choose not to take part. 
• You can agree to take part now and later change your mind. 
• Whatever you decide it will not be held against you. 
• Feel free to ask all the questions you want before you decide. 
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5. Who can I talk to? 
If you have questions, concerns, or complaints, or think the research has hurt you, talk to the 
research team at (215) 553-7123. 
This research has been reviewed and approved by an Institutional Review Board. You may talk 
to them at (215) 255-7857 or email HRPP@drexel.edu for any of the following: 
 
• Your questions, concerns, or complaints are not being answered by the research team. 
You cannot reach the research team. 
• You want to talk to someone besides the research team. 
• You have questions about your rights as a research subject. 
• You want to get information or provide input about this research. 
 
6. Why are we doing this research? 
The purpose of this study is to evaluate the effect of a treatment, problem-solving therapy, 
compared to an enhanced treatment-as-usual condition in reducing stress and high blood 
pressure, and improve quality of life.  This research project is being done in partial fulfillment to 
obtain a doctorate of philosophy in clinical psychology. 
7. How long will the research last? 
We expect that you will be in this research study for approximately 195 minutes (3 hours and 15 
minutes) for the 3 assessments (blood pressure measurements and completion of inventories), 
plus up to about 8 hours of treatment; that is, your overall involvement will entail up to about 
11.25 hours of direct contact over about 5 months. 
8. How many people will be studied? 
We expect about 60 people here will be in this research study out of 60 people in the entire study 
nationally. 
9. What happens if I say yes, I want to be in this research? 
a. You will be asked to participate in 3 assessments (a baseline assessment prior to 
treatment initiation, a posttreatment assessment after treatment is completed or 2 
months, and a follow up assessment 3 months after treatment is completed or 2 months). 
There will be two parts to each of these 3 assessments:  
• A measure of blood pressure using an automatic blood pressure monitor by a 
trained research assistant.  
• Completion of a series of self-report questionnaires that ask you to respond to 
brief questions about your ability to solve real-life problems, your level of stress, 
your quality of life related to your health, symptoms of depression, list of 
prescribed medication and adherence to medications, and lifestyle behaviors like 
physical activity, diet, smoking and alcohol consumption. 
• Overall, each assessment will require approximately 65 minutes of your  time. 
b. This pilot investigation involves random assignment to one of two treatments: 
• The problem-solving therapy involves eight (8) 1-hour sessions that will be 
roughly scheduled about once a week. You will be asked to report any changes in 
prescribed medication while enrolled in the study and blood pressure will be 
assessed approximately every two sessions.  This program is geared to help you 
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(a) better identify those situations that are particularly stressful for you, and (b) to 
help you cope better with them by learning strategies to manage stressful 
situations and emotional reactions. An trained clinical psychology doctoral 
student will provide the eight counseling sessions and will be supervised by a 
licensed clinical psychologist with expertise in delivering this treatment. In an 
effort to ensure the competence and adherence in the delivery of treatment, 
participants will be asked, but not required, to provide permission for the 
treatment sessions to be audio recorded. 
• The enhanced treatment-as-usual condition will involve education material about 
lifestyle changes to reduce high blood pressure and weekly telephone check-ins 
once per week for eight weeks. You will be asked to report any changes 
prescribed medication while enrolled in the study. 
c. Please note that no additional medical tests will be conducted as part of this study. 
d. In order to best understand how effective the treatments are, we ask permission to obtain 
information from your medical records with regard to your medical history only as it 
pertains to your diagnosis and other medical problems.  Specifically, this involves 
details about your high blood pressure/ hypertension diagnosis, such as your height, 
weight, antihypertensive medication changes, blood pressure, heart rate, the presence of 
other cardiovascular problems, and the presence of other common comorbid conditions.  
Such information will need to be contained both prior to, and after, your participation in 
the actual program. 
e. Please note that participating in this study will not interfere with your medical 
procedures at this clinic at any time. The dosage of your anti-hypertensive medication 
may be adjusted by your physician during participation in this study. 
f. Please note that if a blood pressure reading shows that your systolic blood pressure is 
elevated to >/=180 mmHg or diastolic blood pressure is elevated to >/=100 mmHg, the 
referring physician, or a proxy, will be contacted and 911 may be called. 
g. All study-related visits will take place at the ‘Stress and Coping’ Lab offices (3141 
Chestnut St., Stratton Hall, Room 265/229, Philadelphia, PA 19104 or 123 S. Broad St., 
Suite 2040, Philadelphia, PA 19107). 
The treatment you get will be chosen by chance, like flipping a coin. Neither you nor the study 
doctor will choose what treatment you get. You will have a one in two chance of being given 
each treatment. 
10. What are my responsibilities if I take part in this research? 
If you take part in this research, it is very important that you: 
• Follow your physician’s or researcher’s instructions. 
• Tell your study physician or researcher right away if you have a complication or injury. 
11. What happens if I do not want to be in this research? 
You may decide not to take part in the research and it will not be held against you. 
12. What happens if I say yes, but I change my mind later? 
You agree to take part in the research now and stop at any time it will not be held against you. 
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If you stop being in the research, already collected data may not be removed from the study 
database. You will be asked whether the researcher can collect data from your routine medical 
care. If you agree, this data will be handled the same as research data. 
 
 
 
13. Is there any way being in this study could be bad for me? 
The following are risks associated with participating in this study: 
a. Mild distress may occur during or after responding to questionnaires, participating in 
interviews and/or counseling sessions that ask you about the stress you are experiencing. 
b. We predict that even mild distress as a consequence of these activities is rare.  In the 
event that participating in this study leads to some distress, you should remember that 
you can stop at any time without any adverse effects regarding your medical treatment at 
this facility. 
You and your insurance company will be charged for the health care services that you would 
ordinarily be responsible to pay. In some cases, insurance will not pay for services ordinarily 
covered because these services were performed in a research study. You should check with your 
insurance to see what services will be covered by your insurance and what you will be 
responsible to pay. 
 
14. Do I have to pay for anything while I am on this study? 
There is no cost to you for participating in this study.   
15. Will being in this study help me any way? 
We cannot promise any benefits to you or others from your taking part in this research. However, 
possible benefits include better-controlled blood pressure, but there is no guarantee of this. There 
may be no direct benefits to you from participating in this study. 
16. What happens to the information we collect? 
Efforts will be made to limit your personal information, including research study and medical 
records, to people who have a need to review this information. We cannot promise complete 
secrecy. Organizations that may inspect and copy your information include the IRB and other 
representatives of this organization. 
Limitation on confidentiality include if the research team uncovers intent/plan to harm oneself, 
or another, abuse, neglect, or reportable diseases, which may be disclosed to appropriate 
authorities. 
The monitors, auditors, the IRB, the Food and Drug Administration will be granted direct 
access to your medical records for verification of the research procedures and date. By 
signing this document you are authorizing this access. 
We may publish the results of this research. However, we will keep your name and other 
identifying information confidential. 
17. Can I be removed from the research without my OK? 
The person in charge of the research study or the sponsor can remove you from the research 
study without your approval. Possible reasons for removal include: 
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a) A change in your medical condition; 
b) Discontinuation of all or part of the study; or 
c) Other reasons, including new information available to the investigator or harmful 
reasons experienced by you or other subjects in this study. 
If you leave the study before the final assessment, the study research assistant may ask you to 
make a final visit for some of the end of study procedures. 
18. What else do I need to know? 
This research study is being done by Drexel University.   
If you agree to take part in this research study, we will pay you a total of $45 for your time and 
effort in completing the study. If you do not complete the study, you will be paid $5 for 
completion of the first (baseline) assessment, $20 for completion of the second (post-treatment) 
assessment, and $20 for completion of the third assessment (3-month follow up).	  
Federal law provides additional protections of your personal information that are described here. 
Individually Identifiable Health Information That Will Be Collected 
The following personal health information about you will be collected and used during the 
research study and may be given out to others: 
• Your name, address, telephone number, date of birth; 
• Personal and family medical history; 
• Information from laboratory tests, blood and urine tests, x-rays, physical exams and 
other tests or procedures described in this consent form. 
• Information learned during telephone calls, surveys, questionnaires and office visits 
done as part of this research study; 
• Information in medical records located in your doctor’s office or at other medical 
facilities you may have received treatment. 
• Information about financial and social circumstances, or educational level. 
Who Will See and Use Your Health Information within Drexel University  
The researcher and other authorized individuals involved in the research study at Drexel 
University will see your health information during and may give out your health information 
during the research study. These include the researcher and the research staff, the institutional 
review board and their staff, legal counsel, research office and compliance staff, officers of the 
organization and other people who need to see the information in order to conduct the research 
study or make sure it is being done properly. Your health information may be disclosed or 
transmitted electronically. 
Who Else May See and Use your Health Information 
Other persons and organizations outside of Drexel University may see and use your health 
information during this research study. These include: 
• Governmental entities that have the right to see or review your health information, such 
as The Office for Human Research Protections, and the Food and Drug Administration 
• Doctors and staff at the hospital where this research study will take place. 
• A data safety monitoring board. 
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If your health information is given to someone not required by law to keep it confidential, then 
that information may no longer be protected, and may be used or given out without your 
permission. 
Why your health information will be used and given out 
Your information may also be used to meet the reporting requirements of governmental agencies. 
If you do not want to give authorization to use your health information 
You do not have to give your authorization to use or give out your health information. However, 
if you do not give authorization, you cannot participate in this research study. 
How to cancel your authorization 
At any time you may cancel your authorization to allow your health information to be used or 
given out by sending a written notice to Human Research Protection at 1601 Cherry Street, 3 
Parkway Bldg., Mail Stop 10-444, Philadelphia, Pennsylvania, 19102. If you leave this research 
study, no new health information about you will be gathered after you leave. However, 
information gathered before that date may be used or given out if it is needed for the research 
study or any follow-up. 
When your authorization ends 
Your authorization to use and give out your health information will end when the research study 
is finished. 
After the research study is finished, your health information will be maintained in a research 
database. Drexel University shall not re-use or re-disclose the health information in this database 
for other purposes unless you give written authorization to do so. However, the Drexel 
University Institutional Review Board may permit other researchers to see and use your health 
information under adequate privacy safeguards. 
Your right to inspect your medical and research records 
You will not be able to look at your research records while you are taking part in this research 
study. Your personal information will be made available in an emergency if doctors need this 
information to treat you. You can have access to your medical record and any research study 
information when the study is over. However, the researcher does not have to release research 
information to you if it is not part of your medical record. 
Signature Block for Capable Adult 
Your signature documents your permission to take part in this research. 
DO NOT SIGN THIS FORM AFTER THIS 
DATE à  
   
Signature of subject  Date 
  
Printed name of subject 
   
Signature of person obtaining consent  Date 
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Printed name of person obtaining consent  Form Date 
 
 
 
 
APPENDIX D: Measures 
Demographic Information Questionnaire 
 
Please provide the following information. All information will be kept confidential. 
 
 
Sex:     q Female       q Male 
 
Age: ________________ 
 
Race/Ethnicity:         q Asian          q Black (non Hispanic)           q Hispanic/Latino   
q Pacific Islander                 q Native American/Alaskan                q White           
 
q Other _______________________ 
 
Marital status:  q Married/ Living with Partner   q Widowed 
 
q Divorced/ Separated  q Single/ Never Married  
 
q Other _______________________ 
 
# of Household Members: _________________ 
 
Are you currently pregnant?  q Yes        q No      q N/A (Male or post menopausal) 
 
Do you consider yourself religious?:  q Yes  q No 
 
 
 
 
Years of Education:      _________ years (e.g., high school diploma or GED = 12 years)                                         
 
Current Job Status:    q Working full time    q Working part time     
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q Unemployed/ Seeking work            q Volunteering           q Retired           
  
q Receiving disability/ government subsidy       
 
Estimated Yearly Household Income:           q less than $20,000           q $20-40,000  
 
 q $40-60,000               q $60-80,000      q $80-100,000          q more than $100,000 
 
 
 
 
 
When were you first told that you have high blood pressure?: _____ years ago 
 
Additional medical diagnoses:    q Cancer           q Chronic Kidney Disease          
 
q Diabetes                                     q Heart Failure           q Stroke 
 
q Other: ____________________________________________________________ 
 
Is there a history of high blood pressure in your family members?:        
 
                                                q Yes                                     q No 
 
Are there any services you are receiving related to changing behaviors (e.g., weight loss, 
smoking, alcohol, such as AA) or psychological problems (e.g., depression, anxiety)?  
 
    q Yes    q No 
 
If yes, please describe:  
 
 
 
_______________________________________________________________________ 
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Lifestyle Behavior Questionnaire 
 
1) Do you follow the Dietary Approaches to Stop Hypertension (DASH) diet?   
                         q Yes                  q No                          q I don’t know 
 
2) Do you eat foods low in saturated fat, cholesterol and total fat?  
                        q Yes                   q No                          q I don’t know 
 
3) Do you eat fruits, vegetables, and fat-free or low-fat dairy products?  
                        q Yes                   q No                          q I don’t know 
 
4) Do you eat foods rich in whole grains, fish, poultry, beans, seeds, and nuts? 
                         q Yes                  q No                          q I don’t know 
 
5) Do you eat fewer sweets, added sugar or sugary beverages, and red meats than the typical 
American diet?  
                         q Yes                  q No                          q I don’t know 
 
6) Indicate your level of physical activity in the past week (circle one number):   
 
1             2            3         4          5          6         7          8            9             10 
 Light Intensity    Moderate Intensity            Vigorous Intensity 
      (e.g., brisk walking, dancing, gardening)   (e.g., running, fast cycling, aerobics) 
 
7) In the past week, on how many days have you done a total for 30 minutes or more of physical 
activity, which was enough to raise your breathing rate. *This may include sport, exercise, and 
brisk walking or cycling for recreation or to get to and from places, but should not include 
housework or physical activity that may be part of your job.*  __ days  
 
8) What best describes your activity level? Place a check next to one response below: 
________ Vigorously active for at least 30 min, 3 times per week 
________ Moderately active at least 3 times per week 
________ Seldom active, preferring sedentary activities 
 
9) Do you currently use tobacco products (e.g., cigarette, cigar, pipe, etc.)?:     
q Yes    q No 
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If yes: How soon after you wake up do you use the tobacco product? :  
 
_________ After 60 minutes    _________ 31-60 minutes     _________ 6-30 minutes     
_________ within 5 minutes or more 
 
   On average, how many tobacco products do you use per day (e.g., cigarettes smoked)?  
 
________ 10 or fewer            _________ 11-20                 _________ 21-30                 
_________ 31 or more 
 
10) Do you drink alcoholic beverages (e.g., beer, wine, liquor)?        q Yes    q No 
 
If yes: How many alcoholic drinks do you consume, on average, per week?: __________ 
 
q None   q 1-3    q 4-6     q 7-9     q 10-13     q 13-16       q 16-19       q 20 or more 
 
          How many times in the past year have you had 5 (if male) or 4 (if female) or more    
 
           drinks in a day?          _____________ times 
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Social Problem Solving Inventory-Revised: Short Form (SPSI-R:SF) 
 
This measure is copyrighted and therefore excluded from print here. Copyright © 2004 – 2015 
Multi-health Systems Inc. All rights reserved. Please see the following reference for additional 
information regarding the SPSI-R:SF: 
 
D’Zurilla, T.J., Nezu, A.M., and Maydeu-Olivares, A. (2002). Social Problem Solving Inventory 
Revised: Technical Manual. North Tonawanda, N.Y.: Multi-Health Systems. 
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Morisky Medication Adherence Scale (MMAS-8-Item) 
This measure is copyrighted and therefore excluded from print here. Use of the ©MMAS is 
protected by US copyright laws. Permission for use is required. A license agreement is available 
from: Donald E. Morisky, ScD, ScM, MSPH, Professor, Department of Community Health 
Sciences, UCLA School of Public Health, 650 Charles E. Young Drive South, Los Angeles, CA 
90095-1772. Please see the following reference for additional information regarding the MMAS-
8: 
 
Morisky, D. E., Ang, A., Krousel-Wood, M., & Ward, H. J. (2008). Predictive validity of a 
medication adherence measure in an outpatient setting. Journal of Clinical Hypertension, 
10, 348-354. 
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Patient Health Questionnaire (PHQ-9) 
This measure is copyrighted and therefore excluded from print here. PHQ9 Copyright © Pfizer 
Inc. All rights reserved. Please see the following reference for additional information regarding 
the PHQ-9: 
 
Spitzer, R. L., Kroenke, K., & Williams, J. B. W. (1999). Validation and utility of a self-report 
version of PRIME-MD- The PHQ primary care study. Journal of the American Medical 
Association, 282, 1737-1744.  
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SF-12v2 Health Survey (SF-12) 
This measure is copyrighted and therefore excluded from print here. Copyright © 2009, 2010 by 
QualityMetric Incorporated, now part of i3. SF-36®, SF-36v2®, SF-12®, and SF-12v2® are 
trademarks of the Medical Outcomes Trust and are used under license. QualityMetricTM is the 
trademark of QualityMetric Incorporated, now part of i3. Microsoft® is the trademark of 
Microsoft Corporation. The SF-36® Health Survey, SF-36v2® Health Survey, SF-12® Health 
Survey, and SF-12v2® Health Survey are copyrighted by QualityMetric Incorporated and the 
Medical Outcomes Trust. Please see the following reference for additional information regarding 
the SF-12: 
 
Ware, J. E., Kosinski, M., & Keller, S. D. (1996). A 12-Item Short-Form Health Survey: 
Construction of Scales and Preliminary Tests of Reliability and Validity. Medical Care, 34, 
220-233. DOI: 10.1097/00005650-199603000-00003 
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Perceived Stress Questionnaire (PSS) 
 
This measure is copyrighted and therefore excluded from print here. PSS Copyright ©1994 by 
Sheldon Cohen. Please see the following reference for additional information regarding the PSS: 
 
Cohen, S., Kamarck, T., Mermelstein, R. (1983). A global measure of perceived stress. Journal 
of Health and Social Behavior, 24, 385-396. DOI: 10.2307/2136404 
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Program Evaluation 
 
Reducing High Blood Pressure and Stress 
Evaluation of Program 
 
Remembering that all information is confidential, please answer the following questions as 
honestly as possible. Thank you. 
 
A. Using the scale below, from 1 to 5, rate the extent to which you agree with each of the 
statements below by circling the number that best represents your response. 
 
1  2  3  4  5 
Completely                         Agree        Completely   Disagree 
        Somewhat                   Agree 
 
1. I believe that this program has helped me to better manage  
      my high blood pressure.   
     
 
1     2     3     4     5 
 
2.   I believe that this program has helped me to better manage  
      my stress.       
  
 
1     2     3     4     5 
 
3.   I believe that my health coach was competent and has been
 effective in helping me deal better with my problems.  
 
 
1     2     3     4     5 
 
4.   I believe that my health coach was competent and has been  
             effective in helping me make healthy lifestyle changes. 
 
 
1     2     3     4     5 
 
5.   I agree with the ideas that this program is based upon.  
 
1     2     3     4     5 
 
6.   Based upon this program, I am better able to manage my             
stress. 
 
1     2     3     4     5 
 
7.   Based upon this program, I made healthy lifestyle changes.  
 
1     2     3     4     5 
 
8.   I really feel that the program helped me to better control my
 high blood pressure. 
 
1     2     3     4     5 
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9.   I really feel that the program helped  me to reduce my stress.
  
 
1     2     3     4     5 
 
10.  I would confidently recommend this program to other patients 
with high blood pressure. 
 
1     2     3     4     5 
 
 
PLEASE GO TO THE NEXT PAGE 
    
 
B. Please indicate which elements of the program you found particularly helpful. 
 
_______________________________________________________________________ 
 
_______________________________________________________________________ 
 
_______________________________________________________________________ 
 
_______________________________________________________________________ 
 
 
 
 
 
C. Is there anything that you would change in the program to make it better or more 
effective? 
 
_______________________________________________________________________ 
 
_______________________________________________________________________ 
 
_______________________________________________________________________ 
 
_______________________________________________________________________ 
 
 
Thank you for your answers. 
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